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The exogenous expression of master transcription factors (TFs) to drive cell identity 
changes is an exciting and powerful approach to cell and tissue engineering. Yet, the 
generation of desired cell types is often plagued by inefficiency and inability to produce 
mature cell types. Through investigations of the molecular mechanisms of induced 
pluripotent stem cell (iPSC) generation, I discovered that expression of constitutively 
active Smad2/3 (Smad2CA/3CA), together with the Yamanaka factors, could 
dramatically improve the efficiency of reprogramming. Mechanistically, SMAD3 
interacted with both co-activators and reprogramming factors, bridging their interaction 
during reprogramming. Because SMAD2/3 interact with a multitude of master TFs in 
different cell types, I tested the conversions of B cells to macrophages, myoblasts to 
adipocytes, and human fibroblasts to neurons. Remarkably, each conversion system was 
markedly enhanced when the master TFs were co-expressed with Smad3CA. These 
results revealed the existence of shared molecular mechanisms underlying diverse TF-
mediated cellular conversions, and demonstrated SMAD2/3 as a widely applicable co-
factor that potentiates the generation of diverse cell types with profound efficiency and 
maturity. 
Lay Summary 
Stem cells are a cell type capable of generating any tissue and cell of the body. Recent 
advances in cell and molecular biology have enabled stem cells to be used to create cells 
and tissue types that could one day be utilized for regenerative therapies. However, there 
are a number of challenges facing the field before clinical trials take place; chiefly, the 
potential for immune rejection upon transplantation of stem cell derived tissue is a major 
roadblock. A technology exists to produce stem cells from a patient’s own cells, which 
could reduce the immune response upon transplantation. This thesis describes a new 
technology for the production of stem cells from skin cells with improved efficiency. 
Furthermore, the technology can facilitate generation of other clinically relevant cells 
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1.1 Changing cell identity 
1.1.1 Somatic cell nuclear transfer 
 Developmental biologists have for years probed the subject of how specialized, 
or differentiated, cells emerge from unspecialized embryonic cells. For the first half the 
20th century, differentiation hypotheses were centred on the nucleus, suggesting its 
physical and positional properties were manipulated during cell fate specification. Such 
hypotheses often suggested that during development, genes or chromosomes were 
physically sorted or permanently altered, either by deletion or mutation, to give rise to 
somatic cell types. Yet many scientists refused to accept that coordinated deletions and 
mutations in genes occurred in such fine detail, given the infrequent rates of mutation 
they had observed (King and Briggs, 1955). Thus King and Briggs set out to investigate 
if differentiating cell nuclei contained all the genetic information to that of an embryonic 
cell. In the early 1950’s, they developed a technique to transfer the nucleus from one cell 
to another enucleated cell, allowing them to ask an important question: can a nucleus of 
a certain cell type change its function when placed in another cell. The first experiments 
involved transferring early embryonic cells from the frog species Rana pipiens, into 
enucleated eggs of the same species and then observing their capacity to develop. Indeed 
the recipient egg underwent normal development, suggesting that there were at least no 
lasting effects on nuclei during the pre-gastrulation stage of development. They went on 
to test transfers taking nuclei from different developmental stage cells into enucleated 
eggs, demonstrating that in most cases, a fraction of the cells had the capacity to undergo 
normal development up to the blustula or gastrula stage, upon which development 
arrested. King and Briggs then erroneously concluded that the nuclei of later stage 
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developed embryos were restricted as a result of definite nuclear changes during 
differentiation. However, their seminal work influenced another developmental 
biologist, John Gurdon, to further pursue the question of whether a committed adult 
somatic cell nucleus could give rise to adult organisms if presented with optimal 
conditions. Indeed Gurdon first proved that, through optimizing the technique, a small 
proportion (3%) of committed tadpole endoderm cell nuclei could be implanted in 
enucleated eggs which then developed to the tadpole stage of development (Gurdon, 
1960). He then followed that publication by demonstrating that a portion of those eggs 
could fully develop into fertile adults that appeared completely normal (Gurdon, 1962). 
Thus, Gurdon’s studies provided the first evidence that committed somatic cell nuclei 
could be reprogrammed to a pluripotent state. Those results implied that committed 
tissue specific cells, when presented with the right signalling factors and environment, 
contain all the required genetic information to become any other cell type. Further proof 
came from studies showing that adult cells from mammals, such as sheep, could also 
give rise to viable adult clones (Wilmut et al., 1997).  However skeptics rightfully 
questioned the potential that contaminating cells, ones less differentiated, may have 
explained Gurdon and Wilmut’s results. The debate was finally ended in 2002, when a 
group revealed that transferred B-cell nuclei, with traceable genetic rearrangements in 
the immunoglobulin alleles, were efficiently reprogrammed to pluripotency by nuclear 
transfer and produced viable adult mice (Hochedlinger and Jaenisch, 2002).  
  
1.1.2 Forced cell identity changes 
The idea that cytoplasmic factors may contribute to cell identity sprung a new field of 
biological studies. Some of the first direct evidence that cytoplasmic factors direct gene 
expression profiles came from the study of cell fusions. In such experiments, cells are 
grown in close contact, with polyethylene glycol (PEG) added to the media to promote 
cell agglutination and membrane fusion. The result is a multinucleated cell that either 
continues to divide and merge nuclei, or one in which the cell cycle arrests and the cell 
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remains as a multinucleated cell, termed a heterokaryon (Blau et al., 1983). One such 
experiment fused human amniocytes with mouse muscle cells and then probed the 
response of the human nuclei. Through detection of species-specific muscle proteins, the 
authors demonstrated that within 24 hours, the human amniocytes began to express 
muscle genes (Blau et al., 1983). Other researchers began searching for the factors that 
may drive gene expression profile changes, such as those observed in the cell fusion 
studies. A crucial experiment emerged in studies of antenna development in Drosophila 
fruit flies, whereby ectopic expression of a single gene, Antennapedia, at distinct 
developmental stages could alter the body plan of the fly, producing legs where antennae 
normally developed (Schneuwly et al., 1987). In the same year, another group was 
studying the process by which addition of 5-azacytidine was able to convert fibroblasts 
to the highly similar myoblasts cell type in vitro (Davis et al., 1987). Their work lead to 
the identification of 3 genes that appeared uniquely and highly expressed only in 
myoblasts. When they over expressed one such gene, MyoD, they found it was sufficient 
to convert fibroblasts to myoblasts at roughly 50% efficiency (Davis et al., 1987). This 
perhaps represented the birth of the field of forced cell identity changes by over 
expression of transcription factors. 
  
1.1.3 Induced pluripotent stem cells 
In the early 2000’s, the question still remained as to what factors drove the identity 
change of somatic nuclei to a pluripotent state upon nuclear transfer to oocytes. In 2006, 
Kazutoshi Takahashi and Shinya Yamanaka combed the literature and produced a list of 
pluripotency-associated genes, which promoted self-renewal and proliferation in stem 
cells or tumours (Takahashi and Yamanaka, 2006). They hypothesized that over-
expression of these genes could reprogram fibroblasts to pluripotency.  By retroviral 
over-expression of the 24 genes in mouse embryonic fibroblasts, they were able to 
generate induced pluripotent stem cells (iPSCs); it was an astounding breakthrough. 
They then performed sequential depletion of the 24 candidates, narrowing the list to just 
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4 genes; Oct3/4 (O), Sox2 (S), Klf4 (K) and c-Myc (M), as the minimum required 
factors to induce pluripotency in fibroblasts (Takahashi and Yamanaka, 2006).  They 
subsequently showed that adult tail-tip mouse fibroblasts could also be reprogrammed 
with the same 4 factors (Takahashi and Yamanaka, 2006). The resultant iPSCs had 
similar expression profiles to embryonic stem (ES) cells, could be propagated in the 
same media, had demethylation of pluripotency loci promoters, and could form 
teratomas; a tumor which forms upon subcutaneous injection of pluripotent cells into 
adult mice and contains differentiated cells of the three germ layers (Stevens and Little, 
1954; Takahashi et al., 2007; Takahashi and Yamanaka, 2006). As a final proof of 
pluripotency, the mouse iPSCs were injected into blastocysts and were able integrate and 
contribute to the three germ layers of the embryo. Perhaps the only caveat of these 
findings was that the chimeric embryos could not develop to full term adult mice 
(Takahashi and Yamanaka, 2006). However, in less than a year, the Yamanaka lab and 
others successfully produced iPSCs that gave rise to both chimeric and germline 
competent adult mice by targeting a selection cassette to Nanog or Oct3/4, pluripotency 
associated gene loci, enabling more stringent selection conditions (Okita et al., 2007; 
Wernig et al., 2007). Follow-up studies also demonstrated the ability to reprogram 
human fibroblasts to pluripotency (Takahashi et al., 2007).  Thus a powerful and 
reproducible, albeit inefficient, technique had emerged to create genuine pluripotent 
cells from adult somatic cells through the exogenous expression of just 4 transcription 
factors.  
1.2 Dissecting the process of reprogramming 
While the production if iPSCs was highly reproducible among many labs across the 
world, the process itself remained wildly inefficient (~0.01%), and therefore hampered 
our understanding of the molecular details of reprogramming. Most of the initial iPSC 
papers utilized retroviruses to transduce cells with the 4 factors, with significant 
drawbacks of such systems. Firstly, retroviruses can only infect actively proliferating 
cells, which may partially explain the low efficiency of reprogramming observed (Cepko 
and Pear, 2001; Takahashi and Yamanaka, 2006)). Furthermore, the initial studies 
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expressed the 4 factors on individual cassettes, which would result in heterogeneous 
expression, and may have contributed to producing the partially reprogrammed colonies 
observed. The first attempts to address such problems used lentiviral vectors, which can 
infect non-dividing cells, and expressed the 4 factors off a single cassette (Carey et al., 
2009; Shao et al., 2009; Sommer et al., 2009). Such polycistronic cassettes enable more 
uniform production of exogenous factors by linking multiple genes with viral 2A 
sequences. The 2A peptides originate from viral polypeptide sequences and contain a 
well-conserved 18 amino acid sequence. They are found between viral genes and  
mediate protein cleavage during translation. The 2A region initiates a ribosomal ‘skip’, 
whereby a peptide bond is not formed between a proline and glycine within the 2A 
peptides, thus releasing the upstream translated protein from the ribosome while 
allowing continued translation of the downstream transcript (Donnelly et al., 2001; 
Szymczak et al., 2004). While the efficiency of reprogramming increased with the 
lentiviral delivery and 2A polypeptide approaches, there still remained concerns about 
using viruses to produce iPSCs, centralized around concerns of genomic insertion 
mutagenesis as well as aberrant gene activation by viral enhancers in reprogrammed 
cells. Thus, groups sought to reprogram cells with non-viral strategies. The first robust, 
virus-free, reprogramming systems utilized the piggyBac transposon based plasmid 
delivery system containing the 4 factors flanked by the transposase inverted piggyBac 
repeats (Kaji et al., 2009; Woltjen et al., 2009). Transposons are mobile genetic elements 
occurring naturally in the genome, which essentially ‘jump’, or ‘cut and paste’ 
themselves, around the genome. The piggyBac transposable elements are not found in 
the mammalian genome, offering a system that could be utilized for introduction of 
reprogramming factors. The system harbours 2 main advantages over other transposable 
elements: transposition of plasmid into genome is highly efficient, and the transposon 
can subsequently excise itself with extraordinary precision allowing a ‘foot-print free’ 
transgene removal (Wang et al., 2008). Indeed, the Woltjen paper demonstrated not only 
the production of iPSCs, but near perfect excision of the transgene from the established 
iPSC lines (Woltjen et al., 2009).  
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1.2.1 Secondary reprogramming systems 
While the polycistronic, lentiviral and piggyBac systems improved reprogramming 
efficiency, there still remained the challenge that each cell had different numbers of 
reprogramming cassettes inserted in various regions of the genome. Those systems 
produced a heterogeneous group of cells with different levels of reprogramming factor 
expression.  To circumvent such challenges, groups began using established iPSC lines 
to generate so-called secondary reprogramming systems. Such systems rely on 
expression of the 4 factors under control of the doxycycline (dox) inducible tetracycline 
promoter (PTET), thus allowing tight control over reprogramming factor expression. The 
dox system is based upon constitutive expression of the reverse tetracycline 
transactivator (rtTA) protein, which can only bind the tertracycline operator (tetO) and 
activate the PTET promoter in the presence of doxycycline, producing a so-called Tet-ON 
system (Gossen and Bujard, 1992; Urlinger et al., 2000). In secondary reprogramming 
systems, the tetO and PTET sequences are placed on the reprogramming cassette(s) 
upstream of the 4 factors, in conjunction with constitutive rtTA expression in the cells, 
allowing for dox dependent reprogramming factor induction. In one of the first 
secondary reprogramming systems developed, Maurius Wernig and colleagues took 
iPSC lines generated by dox inducible lentiviral plasmids, with rtTA expressed from the 
Rosa26 locus, and generated chimeric mice from the clonal iPSC lines (Wernig et al., 
2008). Upon isolation of various somatic tissue types from the chimeric mice, they 
demonstrated that the addition of doxycycline could activate the integrated 
reprogramming cassettes, initiating successful reprogramming. The secondary system 
exhibited 25-50-fold higher reprogramming efficiencies than the initially reprogrammed 
fibroblast lines (Wernig et al., 2008). Further studies have gone on to use transposon 
based secondary systems, with polycistronic reprogramming cassettes, including lines 
that have a single reprogramming cassette integration (O'Malley et al., 2013; Tonge et 
al., 2014; Woltjen et al., 2009, #468). Such efficient, highly reproducible, secondary 
reprogramming systems have enabled detailed analysis of the reprogramming process, 
from single cell to high throughput genome wide analyses, unlocking the basic 
 
 7 
mechanisms of the reprogramming process.  Yet, reprogramming efficiency is still 
underwhelming with less than 3% of the starting cells making it to a pluripotent state. 
Such low efficiency poses challenges when attempting to perform bulk population 
analyses, as only a small fraction of cells makes it to a pluripotent state. Thus, the time 
point and sub-population of cells used for any analyses must be carefully considered 
with regard to the question asked. 
1.2.2 Cell surface markers to monitor reprogramming progression 
Because the induction of pluripotency from differentiated cells is often asynchronous 
and inefficient, it is necessary to utilize cell surface markers and gene reporters to 
decipher sub-sets of cells en-route to pluripotency. Initially two core strategies were 
envisioned to investigate minor reprogramming populations amongst the mass of cells 
which fail to reprogram: either by monitoring the down-regulation of genes known to be 
expressed in lineage committed cells, and/or by following the gradual activation of 
genes associated with pluripotency. The challenge has been to identify what genes 
strictly represent the pluripotent state or the loss of a given differentiated state.  
 One of the first papers to attempt a combinatorial reporter strategy for 
identification of reprogramming intermediates monitored the loss of the fibroblast (and 
other differentiated cells) surface marker Thy1, gain of signal for the stem cell stage-
specific embryonic antigen-1 (SSEA-1), in conjunction with expression of either Oct4- 
or Sox2-GFP reporters (Stadtfeld et al., 2008). When reprogramming from fibroblasts, 
the majority of cells down regulate Thy1 within 3 days of reprogramming, indicating 
that loss of Thy1 is a common step, but not a major roadblock to reprogramming 
(O'Malley et al., 2013; Samavarchi-Tehrani et al., 2010). Gradual gain of SSEA1 
expression (in Thy1- cells), and subsequent activation of the Oct4/Sox2-GFP reporter, 
allowed for isolation of populations that had increased probability to generate iPS 
colonies (Stadtfeld et al., 2008). However, it has subsequently been shown that SSEA-1 
is expressed heterogeneously in ES cells, and its expression comes on quite early and 
heterogeneously during the reprogramming process, which precludes its use as a reliable 
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marker of early-stage reprogramming populations (Cui et al., 2004; O'Malley et al., 
2013; Samavarchi-Tehrani et al., 2010; Stadtfeld et al., 2008).  Regardless, these early 
works provided the framework for the hypothesis that reprogramming is a step-wise 
process, with cells gradually progressing to more advanced reprogramming states.  
 In 2010, two groups simultaneously published findings describing the acquisition 
of epithelial character as a defining feature of the early to mid-stages of reprogramming 
(Li et al., 2010a; Samavarchi-Tehrani et al., 2010). E-cadherin is critical in the 
establishment and maintenance of pluripotency, is uniformly expressed in ES cells, and 
can replace Oct4 as part of the 4 factor reprogramming strategy (Malaguti et al., 2013; 
O'Malley et al., 2013; Redmer et al., 2011).  Markers of epithelial character, such as E-
cadherin, can be used to identify early populations that are progressing to pluripotency, 
perhaps more stringently than SSEA-1 (Li et al., 2010a; Samavarchi-Tehrani et al., 
2010). 
 Until recently, there remained a rather large gap in our ability to distinguish the 
mid-to-final stages of reprogramming before cells fully engage the core pluripotency 
network. A recent study performed time-course microarray analysis of a piggyBac 
transposon based secondary reprogramming system and revealed the expression of cell 
surface markers CD44 and ICAM1 (CD54) markedly change during the reprogramming 
process (O'Malley et al., 2013). During reprogramming, ICAM1 begins heterogeneously 
expressed in MEF but then quickly becomes low by day 2, and is then up-regulated at 
the late stages of reprogramming concomitantly with many pluripotency genes. Whereas 
CD44 expression begins uniformly high in fibroblasts and is gradually down-regulated 
over the initial-to-mid stages of reprogramming, closely following activation of E-
cadherin expression.  The two surface markers, CD44 and ICAM1, paired with an 
endogenous Nanog-GFP reporter, were utilized to isolate various sub-populations of the 
reprogramming process. As cells lose CD44 expression, and gain ICAM1 expression, 
they correspondingly have greater propensity to generate iPSC colonies, as assessed by 
sorting and re-plating reprogramming experiments (O'Malley et al., 2013). Single cell 
mass cytometry analysis also demonstrated ICAM1 as a robust surface marker of 
successful reprogramming (Lujan et al., 2015; Zunder et al., 2015). Furthermore, global 
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RNA-seq expression profiles of the successive ICAM1/CD44 populations identified 
intermediate and late populations of cells that progressively gain global transcriptional 
profiles similar to ES/iPSCs (O'Malley et al., 2013). Such analyses have elucidated 
reprogramming intermediates and highlighted the distinct stages of reprogramming. It is 
now accepted that conventional 4 factor reprogramming is a step-wise process, 
involving intermediate populations along the path to pluripotency.   
1.2.3 Gene reporters to assess acquisition of pluripotency 
 Often reprogramming efficiency and dynamics are monitored and interpreted 
based upon pluripotency gene reporter expression. However, researchers use caution 
when relying upon a single marker of the pluripotent state given the fact that most, if not 
all, pluripotency genes are not limited to expression in stem cells. A classic example 
would be Sox2; a gene that is a crucial part of the core pluripotency network in a triad 
with Oct4 and Nanog, but also plays a major role in maintaining and specifying neural 
lineages (Gagliardi et al., 2013; Rizzino, 2013; Thiel, 2013; Wang et al., 2012). Recent 
work has also demonstrated lineage-directing roles for Oct4 and Nanog (Karwacki-
Neisius et al., 2013; Wang et al., 2012). Because there is no consensus on a gene 
restricted strictly to expression in the pluripotent state, to be certain the resultant cells 
are indeed iPSCs, it is often necessary to perform other tests such as extended passages, 
transcriptional profiling and various differentiation assays to assess ability to generate 
the three germ layers.  
 The most commonly used reprogramming reporter is Oct4, a master regulator for 
the induction and maintenance of pluripotency (Jerabek et al., 2014; Scholer et al., 1989; 
Takahashi et al., 2007; Takahashi and Yamanaka, 2006). While Oct4 directly binds and 
regulates most of the core regulatory network in ES cells (Chen et al., 2008; Dunn et al., 
2014; Mullen et al., 2011), it is expressed heterogeneously and at high levels during 
differentiation to multiple cell lineages (Karwacki-Neisius et al., 2013; Niwa et al., 
2000; Wang et al., 2012) (Radzisheuskaya et al., 2013). A close look at time-course 
expressional analysis during reprogramming, including in-depth single-cell analysis, has 
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revealed that endogenous Oct4 is expressed early in the process, before Sox2 or Nanog, 
and at or near ES cell levels in intermediate populations and partially reprogrammed 
iPSC colonies (Buganim et al., 2012; Greder et al., 2012; O'Malley et al., 2013; Polo et 
al., 2012). Therefore, using Oct4 as a marker of the pluripotent state may over-estimate 
reprogramming efficiency and mistake partially reprogrammed populations as 
pluripotent.  
 Despite its role in neural stem cells and neurogenesis, Sox2 represents a good 
reporter of pluripotency during reprogramming. Sox2 gene expression is restricted to the 
end stages of reprogramming, with few cells demonstrating expression at intermediate 
stages of reprogramming (Buganim et al., 2012; O'Malley et al., 2013). The activation of 
endogenous Sox2 expression marks a distinct phase of reprogramming marking initial 
establishment of the pluripotency network and maturation toward stable iPSCs 
(Buganim et al., 2012). Sox2 might operate upstream of well-established late stage 
pluripotency associated genes such as Esrrb, Sall4 and Lin28, as suggested by Bayesian 
modelling and over-expression of the downstream factors allowing for reprogramming 
in the absence of Sox2 (Buganim et al., 2012). Recent work using Sox2-EGFP reporter 
MEF demonstrated the protein as a reliable reporter of the pluripotent state and much 
more stringent than an Oct4-EGFP reporter (Lujan et al., 2015). 
 Perhaps the most reliable reporter of the fully reprogrammed state is Nanog, a 
core pluripotency network protein. It is expressed late during the reprogramming process 
(Buganim et al., 2012; Greder et al., 2012; O'Malley et al., 2013), is important for 
establishment of pluripotency in the early embryo (Silva et al., 2009) and can drive 
completion of reprogramming in minimal conditions or transition to naïve pluripotency 
in partially reprogrammed (pre-iPS) cells (Moon et al., 2013; Silva et al., 2009; 
Theunissen et al., 2011).  However, investigations of the various stages of 
reprogramming identified detectable Nanog expression in a subset of early 
reprogramming populations (Buganim et al., 2012; O'Malley et al., 2013). Furthermore, 
Nanog is not required for the maintenance of pluripotency, and recent work has 
demonstrated that Nanog null cells can reprogram to iPSCs, albeit with lower efficiency 
(Carter et al., 2014; Schwarz et al., 2014). While Nanog may not be absolutely necessary 
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for pluripotency acquisition (in vitro) nor maintenance, it may represent the best-tested 
marker of late stage reprogramming and maturation to the pluripotent state.  
 Recent work has highlighted candidate genes that might serve as reliable 
reporters of different reprogramming stages. Time course mass cytometry analysis, 
probing cell surface marker expression during reprogramming, identified CD77 and 
CD49 as transiently expressed genes that mark early reprogramming populations with 
increased probability to successfully reprogram.  Those novel surface markers also 
enabled the identification of gene expression profiles of reprogramming prone 
populations, revealing the previously identified pluripotency genes Nrob1 and Etv5 as 
early up-regulated genes whose expression is important for reprogramming progression 
(Lujan et al., 2015). Such genes represent good candidates to explore early 
reprogramming populations in search of the early events required prior to establishment 
of the complete pluripotency network.  Single cell analysis of 7 distinct stages of 
reprogramming, including 9 clonal populations of partially reprogrammed cell-lines and 
5 established iPS lines, has identified genes which are highly expressed only in late stage 
reprogramming and mature iPSCs.  The work demonstrated factors such as Dppa2, 
Esrrb, Lin28 and Utf1 to be uniformly activated in late stages of reprogramming and in 
colonies representing bona fide iPSCs (Buganim et al., 2012). However, as highlighted 
by single-cell mass cytometry analysis, Lin28 may also mark an alternative 
reprogrammed state, that has yet to be well characterized (Zunder et al., 2015). 
Regardless, the aforementioned genes, or a combination of reporters, may represent the 
best strategy if one seeks to determine the key players involved in establishing a stable, 
uniform network of pluripotent cells. 
 
1.3 The hallmark stages of reprogramming from fibroblasts 
1.3.1 Senescence 
Years after the discovery of iPSCs, despite reprogramming technologies improving, the 
best reported efficiencies remained around 1% of starting cells, highlighting the 
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existence of major unidentified roadblocks. In the summer of 2009, 4 groups 
simultaneously published papers describing senescence as a major reprogramming 
roadblock (Banito et al., 2009; Hong et al., 2009; Kawamura et al., 2009; Li et al., 
2009). Senescence is defined as the irreversible arrest of cell growth, and is often 
associated with the regulation of the INK4a/Arf locus, which encodes 2 critical 
senescence-inducing proteins (Collado et al., 2007). The two proteins are expressed at 
moderate levels in MEF and almost undetectable in ES or iPS cells (Li et al., 2009). 
Within 24 hours of reprogramming factor induction, up-regulation of the core 
senescence network genes p16INK4a, p53, and p21CIP1 occurs (Banito et al., 2009). There 
does not appear to be just one reprogramming factor responsible for senescence 
induction, as independent expression of Sox2, Klf4 or cMyc alone is capable of 
activating expression of the senescence pathway (Banito et al., 2009).  As 
reprogramming progresses, the levels of senescence network proteins transition to lower 
levels of detection (Banito et al., 2009; Li et al., 2009). Those findings suggest that only 
cells that avoid senescence gene up-regulation, or ones that successfully down-regulate 
them can reprogram. Indeed, knockdown of p16Ink4a, p19ARF, p21 or p53, or 
reprogramming of the corresponding knockout MEFs, results in up to 15-fold increase in 
reprogramming efficiency (Banito et al., 2009; Kawamura et al., 2009; Li et al., 2009). 
Strikingly, knockdown or knockout of p53 negates the requirement for Klf4 and c-Myc 
in the reprogramming cocktail, enabling successful reprogramming with just Oct4 and 
Sox2 (Hong et al., 2009; Kawamura et al., 2009). Presently, senescence remains one of 
the best-characterized roadblocks to reprogramming, and is commonly targeted for 
down-regulation in robust reprogramming protocols. 
1.3.2 Sequential activation of pluripotency genes 
Very early in the field of reprogramming research, as one might predict, it became 
apparent that the transition to a pluripotent state happens sequentially in a step-wise 
manner. Work from Rudolf Jaenisch’s lab provided the first evidence, showing the 
pluripotency-associated marker alkaline phosphatase (AP) is activated early and before 
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stage-specific embryonic antigen 1 (SSEA-1). Both AP and SSEA-1 mark the early 
events in the reprogramming process, and precede activation of the pluripotency genes 
Oct4 and Nanog (Brambrink et al., 2008; Stadtfeld et al., 2008). More comprehensive, 
time-course analyses of the sequential nature of reprogramming surfaced years later; 
describing 2 primary waves of pluripotency gene activation, including a late maturation 
phase (Buganim et al., 2012; O'Malley et al., 2013; Polo et al., 2012). While the exact 
timing differs between systems, it has been observed that pluripotency associated genes 
such as Oct4, Sall4, Sall1, Fgf4 are expressed during the first wave at the mid-stages of 
reprogramming, after MET, while Nanog, Sox2, Dppa family members, Esrrb, Lin28 
and Klf2 are expressed in a second wave late in the process (Buganim et al., 2012; 
Golipour et al., 2012; O'Malley et al., 2013; Polo et al., 2012). Many other genes, which 
are not as well characterized in stem cells, fall into one of the two classes of intermediate 
and late stage activation during reprogramming, and require further scrutiny as to the 
relevance of their expression.   
 
 
Figure 1.1 Stages of reprogramming 
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Early after initiation of reprogramming, fibroblast associated genes such as 
Thy1, N-cadherin, Snail and Slug are down-regulated, after which cells gain 
expression of the epithelial markers E-cadherin and EpCAM. Activation of 
the pluripotency network happens later in two general waves: the first 
containing hallmark genes such as Oct4 and Sall4, while the late maturation 
phase is characterized by expression of the core pluripotency network genes 
Nanog and Sox2 among others.  
 
 The final stages of reprogramming involve the silencing of the exogenous 
reprogramming factors, as cells transition to a more stable pluripotent state (Golipour et 
al., 2012; Maherali et al., 2007; Okita et al., 2008; Papapetrou et al., 2009; Wernig et al., 
2007). It was initially observed that high levels of reprogramming factor expression lock 
cells in a unique state, whereby they do not give rise to the three germ layers in 
teratomas (Brambrink et al., 2008). To concisely investigate the so-called ‘maturation 
phase’ of reprogramming, Galipour and colleagues utilized their dox inducible 
reprogramming system to study the affects of dox withdrawal at various end points of 
reprogramming (Golipour et al., 2012). They found that maintenance of high levels of 
MKOS, up to 25 days post induction, could impede activation of late pluripotency genes 
such as Dppa family members, Lin28, Sox2 and Utf1. Within 3 days of dox withdrawal 
and 4-factor down-regulation, the late pluripotency genes were robustly up regulated. 
Indeed, an siRNA screen at day 20 of reprogramming, targeting the genes which were 
up-regulated upon dox withdrawal, resulted in up to 50% reduction in DPPA4+ colonies, 
highlighting the importance of the maturation phase (Golipour et al., 2012). In further 
support, the Yamanaka lab recently reported that, while 20% of transfected human 
fibroblasts express the pluripotency surface marker Tra-1-60 within 7 days of 
reprogramming initiation, only 1% of those become stable, expandable iPSC lines 
(Tanabe et al., 2013). Over-expression of the late pluripotency gene Lin28, enhanced 
stability of sorted and reseeded TRA1-60+ cells, confirming the involvement of such late 
pluripotency genes in iPSC stability (Tanabe et al., 2013).  A subsequent paper 
performing time course analysis of human fibroblast reprogramming also confirmed 
distinct activation of late pluripotency associated genes such as Lin28, Sox2 and 
Dnmt3b, which inversely correlated with the silencing of the reprogramming factor 
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transgenes (Takahashi et al., 2014). Recent work has also identified another unique cell 
population of partially reprogrammed cells associated with high levels of the 
reprogramming factors, termed F-class stem cells, for there ‘fuzzy’ appearance under the 
microscope (Tonge et al., 2014). F-class cells are morphologically and transcriptionally 
distinct from ESCs, but exhibit pluripotent characteristics such as the ability to produce 
teratomas. While the F-class cells are by definition pluripotent, they are reliant upon 
continued transgene expression, and are unable to contribute to chimeras and fail to 
incorporate into blastocysts upon injection. Thus, the maturation phase and generation of 
pluripotent cells that can give rise to chimeric animals, is reliant upon transgene 
silencing/down-regulation, representing a considerable roadblock and important step 
toward stable pluripotency. 
1.3.3 Mesenchymal to epithelial transition  
As reprogramming progresses, one of the earliest observed changes is the loss of 
fibroblast-associated genes and gain of epithelial genes expression, termed a 
mesenchymal-to-epithelial transition (MET). The fibroblast marker Thy-1 silencing 
happens rapidly and near completely very early in the reprogramming process (Li et al., 
2010a; O'Malley et al., 2013; Polo et al., 2012; Samavarchi-Tehrani et al., 2010; 
Stadtfeld et al., 2008). In addition to Thy-1, many other mesenchyme-associated genes 
are robustly silenced early in the reprogramming process, including Snai1, Slug, Cdh2, 
Zeb1, Zeb2 among others (Li et al., 2010a; O'Malley et al., 2013; Samavarchi-Tehrani et 
al., 2010). While mesenchymal associated genes are silenced, epithelial genes such as E-
cadherin (E-cad), multiple claudins, epithelial cell adhesion molecule (Ep-CAM) and 
occludin are robustly activated (Li et al., 2010a; Samavarchi-Tehrani et al., 2010). 
Correspondingly, knockdown or over-expressing E-cad, addition of BMP ligands, or 
over-expression of the micro RNA (miRNA) clusters 200, 205 or 302-367, improves 
reprogramming efficiency through mechanisms hypothesized to enhance the MET (Chen 
et al., 2010; Ichida et al., 2009a; Li et al., 2010a; Liao et al., 2011; Samavarchi-Tehrani 
et al., 2010). However, in each study it is not clear if the observed increase in MET is 
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cause or consequence of increased reprogramming efficiency. While MET has proven a 
hallmark of the early stages of reprogramming, the transition happens quite efficiently in 
robust reprogramming systems (O'Malley et al., 2013), and therefore might not be 
considered a major roadblock to reprogramming n all systems.  However, inhibition of 
TGF-β receptors, a pro-mesenchymal signalling pathway, remarkably enhances 
reprogramming efficiency, suggesting the MET is a barrier to successful reprograming. 
Yet inexplicably, TGF-β inhibitors also improve reprogramming efficiency of epithelial 
cells and promote reprogramming when added at late stages of the process, long after the 
MET has occurred (Ichida et al., 2009a; Li et al., 2010a). It is therefore evident that the 
contribution of TGF-β signalling during reprogramming requires further investigation. 
 
1.4 TGF-β signalling in stem cells and reprogramming 
One of the single most powerful small molecules that can be added to the 
reprogramming media is a TGF-β type I receptor inhibitor, which results in up to 60-fold 
increase in reprogramming efficiency (Ichida et al., 2009b; Li et al., 2010a; Maherali 
and Hochedlinger, 2009). TGF-β signalling is involved in many cellular and 
developmental processes, ranging from maintenance of pluripotency, formation of the 
primitive streak, epithelial to mesenchymal transitions (EMT), lineage specification, 
apoptosis, senescence and proliferation (Derynck and Zhang, 2003; Oshimori and Fuchs, 
2012; Shi and Massague, 2003a). Because of the well established roles for TGF-β in 
EMT, it has been proposed that TGF-β receptor inhibition blocks pro-mesenchymal 
signalling during reprogramming, allowing cells to progress toward the epithelial-like 
pluripotent state (Polo and Hochedlinger, 2010). While TGF-β signalling is involved in 
mesenchymal signalling, it effects multiple other cellular states, which may also 
contribute to the inhibitors affect on the reprogramming process.  The following sections 




1.4.1 Overview of TGF-β signalling 
 Initiation of TGF-β signalling is accomplished by a superfamily of ligands 
consisting of over 30 members, each of which binds specific sub-classes of TGF-β 
associated cell surface receptors (See Figure 4.1 on page 77).  Signalling commences 
upon ligand receptor interaction, initiating type II receptors to associate with, 
phosphorylate and thereby activate Type I receptors. Upon activation, Type I receptors 
initiate downstream signalling with their serine/threonine kinase domains by 
phosphorylating cytoplasmic cofactors such as Smad2/3, MAPK, PI3K/Akt, RhoA, 
TAK1/MEKK1 (Derynck and Zhang, 2003; Oshimori and Fuchs, 2012; Shi and 
Massague, 2003a; Suwanabol et al., 2012). Smad transcription factors are perhaps the 
most instrumental in executing TGF-β receptor signalling. Loss of Smad protein in cells 
severely diminishes or completely abolishes the TGF-β induced response (Li et al., 
2013; Piek et al., 2001; Sakaki-Yumoto et al., 2013). Smads are expressed throughout 
almost all cells and tissues of the body, with signalling regulation occurring via post-
transcriptional modification (Derynck and Zhang, 2003; Oshimori and Fuchs, 2012; Shi 
and Massague, 2003a). Receptor Smad proteins (R-Smad’s) are phosphorylated and 
activated by TGF-β receptors. Upon phosphorylation, R-Smad’s form hetero or 
homodimers and complex with the co-activator Smad4, which stabilizes the interaction 
and facilitates co-factor associations and DNA binding within the nucleus (Chen et al., 
1997; Xi et al., 2011).  Within just 1-2 hours of TGF-β stimulation, Smads have 
transported to the nucleus and elicit differential expression of hundreds of genes (Kang 
et al., 2003; Levy and Hill, 2006; Mullen et al., 2011). 
1.4.2 Smad mediated signalling  
There are 2 main branches of Smad signalling: SMAD2/3 and SMAD1/5/8.  SMAD2/3 
signalling is initiated by TGF-β ligand subfamilies such as TGF-β’s, activin and nodal, 
whereas SMAD1/5/8 signalling is initiated by the ligand subfamilies BMPs (bone 
morphogenetic proteins), GDFs (growth and differentiation factors) and MIS 
(Muellerian inhibiting substance)(Shi and Massague, 2003b). All Smads contain a 
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highly conserved c-terminus MH2 domain with a consensus serine-X-serine (SXS) 
motif, which is the site of phosphorylation by ligand-activated receptors (Abdollah et al., 
1997; Souchelnytskyi et al., 1997). The C-terminal phosphorylated active Smads form 
complexes with other R-Smads and Smad4 and then translocate to the nucleus.  Once in 
the nucleus, Smads act as bipartite transcription factors, working as part of transcription 
regulatory complexes.  
 SMAD signalling inactivation is accomplished largely through the inhibitor 
Smads (I-Smads), SMAD6 and SMAD7. Through direct binding to TGF-β type I 
receptors, SMAD6 and SMAD7 block Smad-activating phosphorylation and also 
facilitate type I receptor ubiquitination and degradation (Derynck and Zhang, 2003; 
Ebisawa et al., 2001; Kavsak et al., 2000). Smad6 can also directly interfere with 
SMAD1/5/8 association with SMAD4, thereby destabilizing the BMP signalling 
pathway. Additionally, SMAD7 can bind DNA at Smad response elements and interfere 
with SMAD2/3/4 interactions with the genome (Zhang et al., 2007). Both SMAD6 and 
SMAD7 are activated transcriptionally by SMAD2/3 or SMAD1/5/8, producing auto-
regulatory negative feedback loops. Furthermore, TGF-β1 ligand stimulation in cells 
initiates rapid SMAD7 translocation to the plasma membrane in complex with the E3 
ubiquitin ligase Smurf, which then target TGF-β type I and type II receptors for 
degradation (Itoh et al., 1998; Kavsak et al., 2000). The regulation of Smad6/7 allows 
for antagonistic competition between the Smad2/3 and Smad1/5/8 signalling pathways. 
For example, inhibition of SMAD2/3 phosphorylation, results in an increase in 
SMAD1/5 phosporylation through a reduction of Smad7 activity (Galvin et al., 2010).  
Conversely, addition of TGF-β ligand to cell cultures down-regulates expression of 
BMP signalling through repression of BMP ligands and receptors (Gronroos et al., 2012; 
Kang et al., 2003; Xu et al., 2008). Thus, there is reciprocal competition amongst the 
Smad2/3 and Smad1/5/8 signalling pathways producing an antagonistic relationship. 
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1.4.3 Smad2/3 mediated transcriptional activation 
 The binding affinity of Smads to DNA is weak, roughly ~100 fold less than other 
high affinity transcription factors (Shi et al., 1998), and therefore Smad-cofactor 
interactions are crucial in specifying interactions with the genome (Derynck and Zhang, 
2003). The consensus Smad binding element (SBE), 5’-AGAC-3’, is common 
throughout the genome and often found in close proximity to recognition sequences of 
other transcription factors (ten Dijke et al., 2000). Despite Smads having low binding 
affinity for the SBE, somewhat inexplicably, their DNA binding is still required for 
transcriptional regulation (Jones and Kern, 2000; Takaesu et al., 2005). In such a model, 
transcription factors recruit Smads to their target loci, Smads then binds the SBE while 
in a complex with the transcription factor and cofactors, which can then remodel 
chromatin and/or regulate transcription (Derynck and Zhang, 2003). The reliance on 
cofactors for recruitment and binding of Smads to DNA produces a transcriptional 
regulatory network that is extremely context dependent (Dennler et al., 1999; Mu et al., 
2012; Shi et al., 1998; Zawel et al., 1998). The widely conserved Smad C-terminal MH2 
domain enables interaction with several transcriptional regulators and nucleosome 
remodelers such as p300/CBP, Mediator, MLL, SWI/SNF, TRIM33 and the 
demethylase JMJD3 (Bertero et al., 2015; Estaras et al., 2012; Kato et al., 2002; Xi et 
al., 2008; Xi et al., 2011). Perhaps the best-characterized Smad3-cofactor interaction is 
with the p300 transcriptional activator (Pouponnot et al., 1998). Smad3 couples with 
p300 as part of the enhanceosome complex, which drives recruitment of cofactors and 
RNAPolII to active sites of transcription (Vo and Goodman, 2001). P300 also 
demonstrates histone acetyltransferase (HATs) activity, which helps remodel 
nucleosomes at target gene promoters to activate transcription (Sterner and Berger, 
2000). The TGF-β transcriptional response is largely dependent upon SMAD3 
interaction with p300 (Pouponnot et al., 1998).  Over-expression of E1A, which 
competes with SMAD3 for p300 binding, inhibits Smad3 dependent transcriptional 
response to TGF-β stimulation. Furthermore, over-expression of p300, or the Smad3-
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p300 cofactor FOXH1, can boost SMAD3 transcriptional activation (Pouponnot et al., 
1998).   
 Smad cofactors often orchestrate transcriptional activation through remodelling 
chromatin at target loci (Gaarenstroom and Hill, 2014). Indeed, most of the well-
established Smad cofactors such as p300, mediator, SWI/SNF and Jmjd3 exhibit 
chromatin remodelling ability. An example of Smad3 assisted chromatin remodelling 
comes from investigations of its interaction with the demethylase JMJD3. SMAD3 and 
JMJD3 cooperate in chromatin remodelling in a number of different cellular contexts 
including regulation of pluripotency, and during endoderm and neural developmental 
programs.  As with most cell types, the SMAD3 binding profile in hESCs and endoderm 
are almost completely unique. As cells exit pluripotency and enter the endoderm 
differentiation program, SMAD2/3 with JMJD3 are localized to endoderm specific 
genes, JMJD3 removes the repressive histone H3 Lys27 (K27) trimethylation 
(H3K27me3) marks, poising endoderm genes for activation (Dahle et al., 2010). The 
recruitment of JMJD3 to endoderm genes requires active SMAD2/3 signalling, and 
inhibition of TGF-β receptors blocks JMJD3 recruitment (Dahle et al., 2010). Similarly, 
in neural stem cell, SMAD3 recruits JMJD3 to neural lineage specific promoters, 
coordinating the neural developmental program both in vitro and in the developing chick 
embryo (Estaras et al., 2012). Within 30 minutes of TGF-β stimulation in neural stem 
cells, JMJD3 is recruited to neural gene promoters, and this response is completely lost 
in the context of Smad3 knock down. The SMAD3-JMJD3 bound genes exhibit 
H3K27me3 reduction within 3 hours of TGF-β activation, and a corresponding increase 
in mRNA expression levels (Estaras et al., 2012). An eloquent in-vivo experiment 
demonstrated that electroporation of a plasmid encoding expression of a constitutive 
active Smad3 (Smad3CA) in the neural tube of chick embryos resulted in enhanced 
neurogenesis from resident neural stem cells. This Smad3CA phenotype was reliant 
upon Jmjd3, as indicated by loss of the phenoypte in the context of Jmjd3 knockdown 
(Estaras et al., 2012). Such experiments have conclusively demonstrated roles for Smad3 
and Jmjd3 cooperating in remodelling chromatin to activate transcriptional programs in 
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diverse cellular contexts, assisting in both the endodermal and ectodermal specification 
programs.   
1.4.4  Developmental roles for TGF-β signalling  
TGF-β signalling first came to the spotlight in the developmental biology field when a 
retroviral insertional mutagenesis screen identified null mutants of Nodal, a TGF-β 
family member ligand, to have an embryonic lethal phenotype (Conlon et al., 1991). 
Nodal-null embryos arrest at the gastrulation stage of development, showing no signs of 
formation of a primitive streak (Conlon et al., 1994; Zhou et al., 1993). Wild-type ES 
cells, at very low contribution, can rescue gastrulation in nodal null chimeric embryos, 
suggesting that minimal, localized Nodal signalling is sufficient to initiate a primitive 
streak and gastrulation (Varlet et al., 1997b). Nodal transcript is initially detected at E5.5 
in the primitive ectoderm, then localizes to the posterior region of the epiblast, and also 
within the visceral endoderm (Conlon et al., 1994; Varlet et al., 1997b). High 
contribution ES cell chimeric rescue (>80% WT cells embryo) of nodal-null embryos, 
revealed that deficient Nodal signalling in the primitive endoderm results in anterior axis 
defects, with embryos exhibiting almost complete absence of the forebrain among other 
anterior neural defects (Varlet et al., 1997b). Because Nodal is required for the 
formation of the primitive streak, it became an attractive hypothesis that Nodal/TGF-β 
signalling was a master regulator of mesoderm fate specification. However, it is clear 
that Nodal null cells do give rise to many mesoderm populations in chimeric embryos 
(Conlon et al., 1991; Conlon et al., 1994; Varlet et al., 1997a; Varlet et al., 1997b). 
Furthermore, Nodal null embryos exhibit marked defects in cells and tissue of all three 
germ layers, suggesting Nodal/TGF-β signalling is involved in many unique 
developmental contexts that are not limited to mesodermal signalling (Conlon et al., 
1994; Varlet et al., 1997b). With a strikingly similar phenotype, deletion of the Nodal 
downstream target Smad2, results in embryonic lethality due to a gastrulation defect 
(Nomura and Li, 1998).   Smad2 null embryos fail to form an organized egg cylinder and 
falter in formation of the mesoderm (Nomura and Li, 1998). Conditional Smad2 null 
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embryos, where the deletion is epiblast specific, can form a primitive streak and undergo 
normal gastrulation, with defects arising in anterior neural patterning in a similar 
phenotype as nodal mutants (Vincent et al., 2003). Thus, like Nodal embryonic roles, 
Smad2 function can be attributed to the extraembryonic signalling centre within the 
anterior visceral endoderm (Heyer et al., 1999; Tremblay et al., 2000; Waldrip et al., 
1998). Intriguingly, null mutation of the highly homologous Smad3, sharing 92% amino 
acid identity with Smad2, does not result in embryonic lethality. Smad3 null embryos 
give rise to juvenile mice, albeit with severe immune dysfunctions, endoderm lineage 
defects and metastatic colorectal cancer in 100% of mice examined (Weinstein et al., 
2001; Yang et al., 1999; Zhu et al., 1998). The strikingly different phenotypes of Smad2 
and Smad3 knockouts, despite high sequence identity and shared regulatory pathways, 
appear to be partly a result of differential expression patterns in the embryo.  Smad2, but 
not Smad3, is expressed in the anterior visceral endoderm, where Smad2 is essential in 
providing the signalling to initiate gastrulation and coordinate anterior-posterior 
patterning (Tremblay et al., 2000). In a single eloquent experiment, Elizabeth 
Robertson’s group demonstrated that inserting Smad3 in the Smad2 null locus, rescues 
the Smad2 knockout gastrulation defect, producing viable, fertile mice, albeit with 
reduced survival (10% Smad3 rescued Smad2 null embryos, as compared to the expected 
25% Mendelian ratio)(Dunn et al., 2004). Those data thereby support the hypothesis that 
regional Smad2/Smad3 embryonic expression facilitates their unique developmental 
roles, and further that SMAD2 and SMAD3 are at least partially functionally redundant. 
 
1.4.5 TGF-β signalling in stem cells  
 Clues as to why TGF-β signalling modulation affects reprogramming may come 
from studies examining the pathways’ role in stem cells. Most studies of Smad2/3 in 
stem cells come from work with human ES cells (hESCs) or the developmentally 
comparable mouse epiblast stem cells (mEpiSCs). Mouse EpiSCs are different from 
conventional mESCs in that they are derived from the post implantation epiblast, rather 
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than the pre-implantation embryo, representing a more primed pluripotent state (Tesar et 
al., 2007). Both mEpiSCs and hESCs are propagated in culture independent of LIF, and 
rely on Fgf and TGF-β signalling for the maintenance of pluripotency (Beattie et al., 
2005; Brons et al., 2007; James et al., 2005; Tesar et al., 2007; Vallier et al., 2005). In 
hESCs TGF-β/activin signalling initiates SMAD2/3 localization to the Nanog promoter 
to drive transcription (Xu et al., 2008). Mutation of the putative Smad2/3 binding 
elements (SBEs) in the Nanog proximal promoter reduces promoter activity and 
responsiveness to activin induced Nanog expression (Xu et al., 2008). Furthermore, 
depletion of Smad2 and/or addition of TGF-β inhibitors, results in abrupt exit from a 
pluripotent state and activation of lineage specific genes (Beattie et al., 2005; James et 
al., 2005; Sakaki-Yumoto et al., 2013; Vallier et al., 2005).  
 In the more naïve mESCs, chromatin immunoprecipitation (ChIP) experiments 
revealed that SMAD3 is bound to >80% of loci bound by the core pluripotency 
transcription factors OCT4, SOX2 and NANOG. Furthermore, a brief 1-hour activation 
or repression of TGF-β signalling, results in significant up or down regulation of the 
SMAD3 bound genes, indicating transcriptional regulatory roles for SMAD3 in mESCs 
(Mullen et al., 2011). However, evidence points to a negative regulation of self-renewal 
by SMAD2/3 in naïve mES cells, as addition of TGF-β ligands induce differentiation 
and inhibitors of TGF-β promote more homogenous Nanog expression and self-renewal 
(Galvin-Burgess et al., 2013; Xi et al., 2011; Ying et al., 2003). It remains unclear why 
the response to TGF-β signalling is completely contradictory when comparing mouse 
naïve and EpiSCs. 
 The TGF-β antagonistic BMP pathway promotes differentiation in hESCs and 
mEpiSCs (Pera et al., 2004; Xu et al., 2002; Xu et al., 2005).  Treatment of hESCs with 
BMP2, BMP4 or BMP7 drives the cells to differentiate toward various lineages 
including endoderm (BMP-2, -4, or -7 addition), or trophoblast-like cells (BMP-4) 
(Mummery et al., 2003; Xu et al., 2002). Treatment with the BMP inhibitor NOGGIN 
allows for expansion and maintenance of an undifferentiated state in the absence of 
fibroblast feeders, which at the time were required to hESC maintenance (Xu et al., 
2005). The BMP downstream targets SMAD1/5/8 bind the Nanog promoter in hESCs 
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within 24 hours of BMP4 induction, coinciding with exit from an undifferentiated state, 
suggesting they may act in an inhibitory role at the Nanog promoter (Xu et al., 2008).  
 The roles of TGF-β and BMP signalling in self-renewal are almost completely, 
and somewhat inexplicably reversed when investigating naïve mES cells. Foremost, 
mouse ES cells are maintained in the absence of feeders with LIF and BMP4 (Galvin-
Burgess et al., 2013; Ying et al., 2003).   Ying et al first identified that BMP4 maintains 
pluripotency by blocking ES cell differentiation into neural lineages (Ying and Smith, 
2003). They subsequently demonstrated that BMP4 (or GDF6, another SMAD1/5/8 
activating ligand) and Leukemia inhibiting factor (LIF) alone were sufficient to maintain 
pluripotency in the absence of serum.  The mechanism by which BMP acts is in part 
through up regulation of Id proteins, which bind to and block the activity of some of the 
bHLH family of pro-neural transcription factors (Ying et al., 2003). Other groups have 
also demonstrated that addition of BMP4 suppresses Mitogen activated protein kinase 
(MAPK) and extracellular receptor kinase (ERK) pathways, which also helps prevent 
differentiation (Qi et al., 2004a). Thus, it appears that rather than maintaining the 
pluripotency network of ES cells, BMP’s play important roles in dampening 
differentiation cues.  Interestingly, over-expression of Nanog superseded the 
requirement for BMP signalling to maintain ES pluripotency in serum-free media. 
Furthermore, Nanog over-expression is sufficient to activate Id genes (Ying et al., 2003). 
These findings bring to question the targets of BMP signalling in ES cells, specifically 
questioning whether BMP signalling directly induces Id expression, synergizes with 
NANOG to activate Id’s, or indirectly activates the upstream pluripotency network. 
 
1.4.6 Modulating TGF-β signalling during reprogramming 
 In the reprogramming context, modulation of TGF-β (SMAD2/3) and BMP 
(SMAD1/5/8) signalling has resulted in conflicting reports. Initial reports demonstrated 
that addition of BMP during reprogramming results in a 3-fold increase in 
reprogramming efficiency (Samavarchi-Tehrani et al., 2010). They further demonstrated 
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that BMPs act in part by activating the microRNA (mRNA) 200 family members, which 
are involved in promoting the mesenchymal to epithelial transition (MET) (Samavarchi-
Tehrani et al., 2010). However, those results relied upon the early expressed 
reprogramming marker alkaline phosphatase staining as a read-out of successful 
reprogramming. More comprehensive analyses revealed that BMPs, present in the fetal 
calf serum (FCS) of reprogramming media, lock cells in a partially reprogrammed state 
and that inhibition of BMP signalling allows the so called pre-iPS cells to convert to 
mature bona fide iPSCs (Chen et al., 2013b). BMPs activate methyltransferases, such as 
Setdb1 and Suv39h1, which maintain repressive histone 3 lysine 9 methylation marks at 
pluripotency loci, acting as a barrier to reprogramming (Chen et al., 2013b). While 
BMPs may beneficially promote the early stage MET, at later stages of reprogramming 
the BMP pathway must be silenced to promote and stabilize the pluripotent state.  
 Investigations of the SMAD2/3 pathway have demonstrated that, in general, 
activation with TGF-β ligands reduces reprogramming efficiency while use of small 
molecules to inhibit the pathway results in a remarkable increase in reprogramming 
efficiency (Ichida et al., 2009a; Li et al., 2010a; Maherali and Hochedlinger, 2009). The 
Hochedlinger lab demonstrated that the TGF-β type I receptor inhibitor Alki (Alk5i), 
could increase reprogramming efficiency up to 60-fold (Maherali and Hochedlinger, 
2009). The Alki was most effective when added during the first 8 days of 
reprogramming, exhibiting little effect when added at late time-points (Maherali and 
Hochedlinger, 2009). However, Ichida and colleagues demonstrated that, when 
reprogramming with just Oct4, cMyc and Klf4, the optimal time to add the Alki was day 
10-22, showing improved efficiency over inhibition at early stages or during the entire 
reprogramming process (Ichida et al., 2009a).  Therefore, not surprisingly, it seems 
TGF-β signalling during reprogramming is context dependent. The inhibitor was 
proposed to alleviate mesenchymal signalling, promoting MET at the early stages of 
reprogramming (Polo and Hochedlinger, 2010). However, addition of the Alki to 
epithelial cells still exhibits a 2-10 fold increase in reprogramming efficiency, 
suggesting other mechanisms are involved (Li et al., 2010a). Interestingly, alternative 
approaches to inhibit the TGF-β pathway with receptor blocking antibodies, does not 
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have near the positive affect as the Alki or SB43 receptor inhibitors (Ichida et al., 
2009a). Furthermore, over-expression of TGF-β receptors, to boost pathway activation, 
only mildly inhibits the reprogramming process (Li et al., 2010a). Complicating matters 
further, is the recent evidence that exposure to TGF-β ligand for the first 3 days of 
reprogramming increases the generation of IPSCs by 2 to 3 fold (Liu et al., 2013). It 
seems, in a similar fashion to BMPs, TGF-β signalling may provide some benefit in 
early-intermediate reprogramming populations but must be silenced to reach the final 
pluripotent state.  In any case, it is evident that modulation of TGF-β/BMP and Smad 
signalling has substantial implications to the outcome of reprogramming experiments 
and deserves further investigation. 
1.4.7 Master transcription factors direct Smad3 to target loci 
TGF-β stimulation or repression results in over 2-fold differential expression of several 
hundred genes within hours of treatment (Kang et al., 2003; Levy and Hill, 2006; Mullen 
et al., 2011). The genes and pathways targeted are highly context dependent, ranging 
from cell proliferation, senescence and apoptosis to maintenance of pluripotency and 
activation of development transcriptional programs (Derynck and Zhang, 2003). A clue 
to the contextual complexity of TGF-β signalling emerged in a recent paper 
demonstrating that master transcription factors direct Smad3 binding to their respective 
target loci (Mullen et al., 2011). Genome-wide Smad3 binding sites were assessed in ES 
cells, pro-B cells and myotubes, identifying that SMAD3 bound regions are almost 
entirely unique in each cell type, with only 1% overlap. Smad3 co-localized to over 70% 
of genomic loci with the master transcription factors OCT4, SOX2 and NAOG in ES 
cells, PU.1 in pro-B cells and MYOD1 in myotubes. Upon TGF-β stimulation or 
inhibition, only the genes that were bound by SMAD3 and master transcription factor 
were differentially regulated in the respective cell type. Interestingly, over-expression of 
MyoD1 in ES cells was able to recruit SMAD3 to MYOD1 binding sites in ES cells, 
while Smad3 also remained bound at pluripotency loci. Those findings nicely 
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demonstrated that master transcription factors recruit SMAD3 to their target loci and 
that the transcriptional output of the system depends on levels of TGF-β/Smad3 activity. 
 The aforementioned examples of diverse Smad2/3 actions in unique cellular 
contexts demonstrate that Smad’s serve as cofactors potentiating transcriptional 
regulation at genomic regions as specified by master transcription factors. In the context 
of cell identity changes, such as those occurring during development, it is crucial to have 
tight control of timing and amplitude of gene expression. With the ability to modulate 
Smad signalling through TGF-β ligand gradients, such a system would impart cells the 
ability to tightly regulate master transcription factor signalling output. In the context of 
forced cell identity changes with master transcription factors, such as the reprogramming 
of somatic cells to pluripotency, it has been previously demonstrated that tight regulation 
of TGF-β signalling is instrumental to successful reprogramming. Yet, little is 
understood as to the roles of TGF-β signalling throughout the process. 
 
1.5 Aims of this thesis 
The aim of this work is to characterize the contributions of TGF-β signalling during 
reprogramming to pluripotency. Secondarily, the work will test the hypothesis that 
discoveries of TGF-β function during reprogramming might benefit other forced cell 
identity conversions with master transcription factors. When considering the large cohort 
of identified TGF-β target genes, there may be a multitude of mechanism through which 
these signalling pathways alter the dynamics of cell identity conversions.   While many 
publications have suggested that TGF-β inhibition during fibroblasts reprogramming to 
iPSCs blocks mesenchymal signalling, promoting the acquisition of epithelial character, 
most works have not distinguished if such observations are the cause or consequence. 
Through a combination of reprogramming surface marker expression dynamics, a 
Nanog-GFP pluripotency reporter, monitoring SMAD2/3 activity, and over-expression 
of constitutive active Smad2/3 constructs, these works explore the contributions of TGF-
β signalling during reprogramming and apply those findings to other cell identity 
conversion systems.   
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1.6 A brief overview of findings from this work 
The first objective was to monitor the mesenchymal to epithelial transition 
during reprogramming, revealing that the TGF-β receptor inhibitor (Alki) did not 
accelerate the up-regulation of E-cadherin. FACS analysis and sorting with 
reprogramming stage-specific surface markers CD44 and ICAM1 revealed that the Alki 
boosts intermediate stage transitions during reprogramming, long after the mesenchymal 
to epithelial transition occurs. To explore the downstream mechanism of Alki action, the 
canonical TGF-β pathway transcription factor Smad3 was targeted with a specific 
inhibitor of Smad3 (SIS3). Unexpectedly, the SIS3 was unable to recapitulate the Alki 
results; SIS3 almost completely inhibited reprogramming. Following those results, the 
activity of SMAD3 during reprogramming was monitored by immunofluorescence with 
a phophorylated-SMAD3 (pSMAD3) specific antibody, which recognizes the active 
form of SMAD3. Unexpectedly, pSMAD3 levels were higher in the presence of Alki 
during reprogramming. Furthermore, cells with high levels of pSMAD3 were also 
expressing the highest levels of Nanog-GFP reporter. Those results suggested that the 
level of active SMAD3 is somehow increased in the presence of Alki, perhaps due to a 
skewed negative feedback loop, which might be crucial for enhanced reprogramming by 
Alki. This hypothesis lead to an experiment whereby a constitutive active Smad3 
(Smad3CA), or Smad2CA, was over-expressed during reprogramming. Strikingly, 
Smad3CA or Smad2CA drastically boosted the efficiency of reprogramming over 6-fold, 
driving Nanog-GFP expression and substantially accelerating the reprogramming 
process. Global RNA-seq analysis confirmed that reprogramming intermediate stage-
specific transient gene up-regulation is less evident in the presence of SMAD3CA, 
indicating SMAD3CA drives cells toward a pluripotent state on a more direct route. Co-
immunoprecipitation studies then revealed interactions between SMAD3 and the 
reprogramming master transcription factors OCT4, SOX2 and to a lesser extent KLF4. 
SMAD3 also interacted with a multitude of chromatin remodellers and transcriptional 
activators during reprogramming. Finally, because SMAD2/3 are well characterized to 
interact with cell type specific master transcription factors, transdifferentiation systems 
were investigated to explore if Smad3CA could boost other cell identity conversions in 
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collaboration with Thomas Graf’s and Malin Parmar’s laboratories. Indeed, expression 
of Smad3CA boosted the conversion of B cells to Macrophages, myoblasts to 
adipocytes, and fibroblasts to neurons. These results reveal Smad2/3 as potent amplifiers 
of cell identity conversions with master transcription factors and identify a powerful tool 






2: Materials and Methods 
 
2.1 Cell culture  
2.1.1 Cell culture reagents 
ES medium: 
o Glasgow Minimal Essential Medium (GMEM, Sigma G5154)    
o Fetal Calf Serum (FCS)  (10%) (Life Technologies)      
o Non essential amino acids (1x, Gibco 11140-035)      
o L-Glutamine (2 mM, Invitrogen)    
o Sodium pyruvate (Invitrogen)   
o 100 U/ml LIF (human recombinant, made in house)    
o Penicillin/Streptomycin (100 units/100 ug, Sigma P4333) 
 
MEF medium: 
o ES media  
o FGF2  (5 ng/mL, Peprotech, 100-18-B)       
o Heparin  (1 ng/mL, Sigma) 
 
Reprogramming media: 
o ES media 
o Doxycycline (300 ng/ml for reprogramming of targeted cell lines or 1000 ng/ml 
for primary reprogramming) (Sigma)   
o Ascorbic Acid (VitaminC) (10 ug/mL, Sigma 1000731348)      
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o +/- ALKi (A83-01) (500 nM, TOCRIS Bioscience #2934)      
o +/- SB43 (SB431542) (10 uM, TOCRIS Bioscience, #1614) 
 
PlatE media: 
o ES media (10 µg/ml) 
o Puromycin (1 µg /ml) 
o Blasticidin (10 µg /ml) 
 
Freezing solution:       
o DMSO (10%, VWR International)       
o FCS (90%) (Life Technologies)  
 
Other reagents: 
o Gelatin (0.1% in PBS, Sigma G5154)   
o Trypsin (0.25%, Gibco 15090-046)    
o EDTA (0.1%, Sigma 03620)    
o PBS (Sigma, D8537) 
o Accutase (Sigma, A6964)  
 
2.1.2 Cell lines used  
o TNG-MKOS 
o 129 or CD1 derived MEF 
o PlatE viral packaging line 
 
 The cell line used for reprogramming, termed TNG-MKOS, has been described 
in a recent publication (Chantzoura E.; Skylaki, in press). Briefly, a mouse ESC line 
(TNG ESC line) harbouring a targeted Nanog-GFP (TNG) reporter with GFP coding 
sequence at the first ATG site of the Nanog exon 1 was provided by Dr. Chambers. With 
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this cell line, expression of GFP reports the endogenous Nanog promoter activity, while 
also producing a Nanog heterozygous mutant (Chambers, 2007). Furthermore, the GFP 
cassette in the Nanog locus has an IRES-puromycin resistance gene cassette, enabling 
selection of Nanog-GFP expressing cells. A doxycycline inducible polycystronic 
cassette with the 4 reprogramming factors c-Myc (M), Klf4 (K), Oct3/4 (O), Sox2 (S) 
linked by 2A peptides, followed by an internal ribosome entry site (IRES) mOrange 
reporter and a CAG promoter driven-rtTA (doxycycline transactivator) expression 
cassette was integrated into the TNG ESC line in to the Sp3 locus via gene targeting.   
The Sp3 locus had been identified to be conducive to reprogramming from random 
integration of piggyBac transposon carrying a dox-inducible reprogramming cassette 
previously (O'Malley et al., 2013).  
 The wild type (wt) MEFs used for reprogramming experiments were derived 
from the mouse strain 129 or CD1. MEF were harvested as described below. 
 The PlatE viral packaging system was used for retroviral mediated gene delivery. 
The platE line was previously created by transfecting the 293T cell line with EF1α 
promoter driven cassettes expressing the gag-pol and env viral packaging genes 
followed by IRES-blasticidin/puromycin resistance sequences to enable maintenance of 
high titer lines (Morita et al., 2000). Viral mediated gene transduction is described in 
more detail below.   
2.1.3 Cell passaging 
Both ES and MEF were cultured until ~80-90% confluent at which point they were 
passaged at a ratio of 1:5 or 1:3 respectively. Passage was performed by 1 wash with 
PBS, followed by 3 minutes treatment with Trypsin (0.25%) EDTA (2 mM) then re-
suspended in medium and centrifuged at 300 g for 3 minutes prior to re-suspension in 




2.2 Reprogramming experiments 
2.2.1 Generation of reprogrammable MEF 
 The TNG-MKOS ESC line was used to produce chimeric embryos by morula 
aggregation. Prior to morula aggregation, cells were plated at 2X serial dilutions starting 
from 2x106 cells down to 62.5x105 cells. The next day, colonies of 5-8 cells were then 
selected for aggregation with morulas (2.5 d.p.c) of C57B1/6 mice. The staff at our in-
house transgenics facility carried out the procedures, as previously described (Pluck and 
Klasen, 2009). The implanted chimeric embryos from morula aggregation were 
harvested at E12.5 for MEF isolation (described below) and reprogramming. 
 To generate reprogrammable transgenic mouse lines, we performed blastocyst 
injection with the TNG-MKOS ESC line. The resulting chimeric mice (recipient 
C57B1/6 + ESC 129 background) were crossed with CD1 mice. We chose CD1 mice 
because they breed well, different from 129 mice, and the maintenance of CD1 ESC 
lines is as easy as that of 129, easier than from that of C57B1/6. Nanog+/GFP,Sp3+/tetO-
MKOS, CAG-rtTA F1 male mice were used as breeders.  One quarter of the pups from the F1 
x wt CD1 breeding were the desired genotype as we expected from the Mendelian 
inheritance ratio. 
2.2.2 Extraction of MEF for reprogramming 
Embryos were dissected from culled mothers at E12.5 for harvesting of MEF. The 
embryos head was removed (saved for genotyping) and the body was eviscerated and 
placed in 0.25% trypsin EDTA for 10 minutes at 37oC. They were further dissociated by 
passage through an 18-gauge needle 10 times, prior to another 5 minutes incubation at 
37oC.  Trypsin was inactivated with MEF media, then cells were centrifuged and re-
suspended in MEF media and plated into a 10 cm plate; 1 embryo per plate. MEF were 




2.2.3 Genotyping embryos 
The head or endoderm of embryos was added to 25 µl of lysis buffer containing 25mM 
NaOH, 0.2 mM EDTA and incubated at 95° for 20 minutes, then cooled to 4 °C. Then 
25 µl of neutralization buffer containing 40 mM Tris HCl (pH 5.0) was added and the 
sample was vortex mixed for 10 seconds. The final solution contains 20 mM Tris/0.1 
mM EDTA/pH 8.0 with 12.5 mM sodium ions. For PCR reaction, 1 ul of lysate DNA 
solution was used for a 15 ul PCR reaction containing: 1 ul DNA solution, 1 µl each of 2 
µM primers, 0.075 ul DreamTaq polymerase (Thermo Scientific), 7.5 µL 2X buffer, 2µL 
dNTPs, 2.425 ddH2O. PCR was run with primers specific to one or all of 
Nanog/GFP/rtTA (primer table below) as necessary, using standard PCR protocol 
involving a pre-incubation at 95oC for 3 minutes, 20 Cycles of 95oC/60oC/72oC for 
10s/5s/30s respectively, followed by a 5 minute incubation at 72oC and storage at 4oC 
indefinitely.  
 
Name Sequence Genotype Amplicon 
size (bp) 
N-Ex1 F CTGAGGAAGCATCGAATTCTGG Nanog wt allele 186 
N-Int1 R AAGCAATAACCCTTCAGCCC Nanog wt allele 186 
IC346 F ATATGGCCACAACCATGACC Nanog-GFPiPuro 211 
IC347 R ACCCACACCTTGCCGATGTC Nanog-GFPiPuro 211 
mO F1 ACCATGGTGAGCAAGGGCGA MKOSimOrange 241 
mO R1 GCTTCACGTAGGCCTTGGAG MKOSimOrange 241 
Table 2.1. Primers for genotyping 
A list of primers for genotyping MEF for reprogramming 
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2.2.4 TNG-MKOS MEF reprogramming 
 I used 2 general strategies for reprogramming experiments, which involve a 
starting population of either 5% transgenic reprogrammable MEF amongst 95% wt 
feeder MEF, or 100% transgenic MEF to start. The majority of experiments in this work 
are from the 5% starting transgenic cell experiments; conditions which were previously 
established as optimal for our reprogramming system. However, some experiments 
require a large quantity of cells undergoing reprogramming without contamination of wt 
MEFs, such as those for ChIP-qPCR. In these cases, I used 100% transgenic cells to 
avoid requirement of cell sorting. Whether starting with 5% or 100% transgenic cells, 
the reprogramming conditions remain the same. 
 MEF are defrosted at high confluence (>70%) in MEF media 2-3 days prior to 
plating for reprogramming. For 5% transgenic cell reprogramming, one day prior to 
initiating reprogramming, the cells are seeded on gelatin pre-coated plates at 1x105 total 
cells for 1 well of a 6-well plate, or 7x105 total cells for a 10cm plate, which is 5x104 or 
3.6x105 transgenic cells respectively. For 100% transgenic cell reprogramming 
experiments, 5x104 or 5x105 transgenic cells are plated in 1 well of a 6 well or 10 cm 
dish respectively. One day after plating, MEF media is replaced with reprogramming 
media containing doxycycline (dox) to activate expression of MKOS reprogramming 
factors. Reprogramming media is replenished every 2 days until the end of the 
experiment.  
2.2.5 Retroviral mediated gene transduction 
 Viruses can be exploited as gene delivery tools to package, transduce and express 
genes of interest into the mammalian genome (Cherry et al., 2000; McTaggart and Al-
Rubeai, 2002; Vu et al., 2008). In these studies we utilized the pMXs retroviral gene 
delivery system (Kitamura et al., 2003).   Retroviral systems deliver viral RNA into the 
host cell nucleus, which then gets reverse transcribed by a viral packaged reverse-
transcriptase into a DNA template and is incorporated into the host genome via long 
terminal repeats (LTRs), aided by the viral integrase (McTaggart and Al-Rubeai, 2002). 
 
 36 
Upon genome insertion, the 5’ LTR drives transcription of the viral DNA insert. For 
introducing a gene of interest into host cells, one can clone any gene into the viral 
genome plasmid between the LTR sites, which, upon viral production and transduction, 
will be incorporated into the host genome and be transcribed (Kitamura et al., 2003; 
McTaggart and Al-Rubeai, 2002).   For safety and efficacy, all of the necessary genes 
encoding viral packaging proteins were stably transfected into a viral packaging cell line 
called PlatE, such that viral replication genes are not packaged into the viral particles. 
The PlatE cell line constitutively expresses the gag-pol and env packaging genes, 
allowing for production of a virus coding for integration and expression of a gene of 
interest with transfection of a single plasmid, that cannot produce more virus in the 
infected cell (Morita et al., 2000). 
 For reprogramming experiments, the pMXs system was used because it exhibits 
far less toxicity in MEF as compared to the highly infectious lentiviral packaging 
systems (observations from our lab). The pMXs retroviral expression system was used to 
over-express genes of interest (GOI) in our TNG-MKOS reprogramming system. For 
retroviral production, the PlatE cell line was grown to ~80% confluence, and then 
1.6x106 cells were plated in a 10 cm dish in 8 ml of media. One day later the cells were 
transfected with a pMx viral vector coding for expression of a gene of interest (GOI) 
(see plasmid list). Transfection was carried out using the CaCl2 based delivery method 
(Kingston et al., 2003). Briefly, 10 µg of pMXs-GOI DNA was made to a final volume 
of 427 ul in H2O, then added to 63 ul 2M CaCl2 and mixed well; the DNA-CaCl2 
mixture is added into 500 ul 2X HBS (8 g NaCl, 0.2 g Na2HPO4-7H2O, 6.5 g HEPES in 
500 ml H2O, pH 7) by pipetting repeatedly, and then 800 µl of the final mixture was 
added to the PlatE in 8 ml of media. After 24 hours, the transfected PlatE cell medium 
was changed, and virus was allowed to accumulate in the media for 24 hours, at which 
point viral infection was initiated. Viral infection is initiated by first filtering the virus 
containing supernatant through 0.45 µM Whatman cellulose acetate filters to remove 
contaminating PlatE cells and then adding polybrene (Merck-Millipore) at 8 µg/ml to the 
supernatant to enhance viral particle absorption in MEF (Davis et al., 2002). The 
supernatant is then added to the MEF, 2ml in a well of a 6-well, or 8 ml into a 10 cm 
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plate. The MEF were exposed to viral supernatant for 6 hours at 32 oC (7.5% CO2), and 
then media is changed to reprogramming media and plates are placed back at 37 oC 
(7.5% CO2). All virus procedures were performed in a designated retroviral hood, 
according to established lab viral protocols. 
 
2.2.6 Generation of Smad2CA/3CA with site directed mutagenesis 
To create the Smad2CA/3CA expression constructs, the cDNA of the genes was cloned 
using primers that introduce base pair changes in the genes. For Smad2CA/3CA 
expression constructs, PCR primers were designed with base pair mismatches at the 3’ 
end, to exchange serine codons for aspartic acid (SSVSDDVD*) in Smad3, or 
glutamic acid (SSMSSEME) in Smad2, in the C-terminus of the proteins (Chipuk et 
al., 2002; Funaba and Mathews, 2000). The primers used for mouse Smad2 were 
forward- CTAGGGTAGATTTACCGGGC, Reverse-
CGAGTCTTTGATGGGTTTACTCCATCTCTGAGCATCGCACTGAA, and for 
Smad3 forward- 
GCTGGCGCCGGAACCAATTCAGTCGACGTGACCCTTCGGTGCCAG, reverse-
CTAATCCACATCGTCACAGCGGATGCTCGG GGAACCCATCTGGGT. Primers 








CTTGGGGA. The PCR products were then cloned into the TOPO Blunt vector and 




2.2.7 Sorting and re-plating reprogramming experiments 
For some experiments, cells were sorted and re-plated for continued reprogramming. In 
such experiments, cells were sorted into FACS buffer (2% FCS in PBS) and then re-
plated onto gelatin coated 6-well plates in reprogramming media. They were seeded as 
5x103 or 1x104 cells into 1 well of a 6-well, depending on stage of reprogramming. Cells 
were reprogrammed for an additional 10 days, prior to Nanog-GFP+ colony counting. 




























control vector pMXs-dsRed LTR-BFP LTR Ampicillin 
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(Yusa et al., 
2011) CMV Ampicillin 
Table 2.2. Plasmids for reprogramming 
A list of plasmids used in various reprogramming experiments. 
2.3 Florescence Activated Cell Sorting (FACS) 
 
Antibodies: 
o CD44-biotin conjugate (1:100 dilution) (eBioscience 13-0441) 
o CD44-APC conjugate (1:300 dilution) (eBioscience 17-0441) 
o Icam-1/CD54-biotin conjugate (1:100 dilution) (eBioscience 13-0541) 
o E-cadherin-eFluor660 conjugate (1:300 dilution) (eBioscience 50-3249-82) 
o Strepdavidin PE-Cy7 (1:1500 dilution) (eBioscience 25-4317) 
2.3.1 Cell preparation for FACS 
 Cells were lifted with Trypsin-EDTA or Accutase (for E-cadherin experiments) 
for 5 or 15 minutes respectively. Trypsin/accutase was inactivated in serum and then 
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cells were spun and re-suspended in FACS buffer (2% FCS in PBS). Cells were washed 
twice in FACS buffer, re-suspended at ~1x106 cells per 300 µl, prior to staining with 
primary antibodies, on ice for 10 minutes. Cells were centrifuged at 300g for 3 minutes 
prior to 3 washes in PBS and then re-suspended to 1x106 cells in FACS buffer with 
secondary antibodies and incubated on ice for 5 minutes. Stained cells were then washed 
3 times in PBS, filtered in a 40 µM mesh filter (BD) prior to re-suspension in FACS 
buffer at original volume and then processed using FACS analysis or sorting.  FACS 
sorting or analysis were carried out on the BD FACS AriaII or Fortessa respectively, 
according to conditions as outlined in (O'Malley et al., 2013), and summarized below.  
Laser voltages varied and were adjusted each time according to controls. 
2.3.2 FACS settings 
  Laser   
Band filter 488nm   561nm   640nm  
530±30   GFP     
582±15     mOrange   
670±30     APC 
780±60      PE-Cy7   
Table 2.3. FACS settings  
Laser refers to the wavelength of light the fluorophore bound sample was 
excited with. The band filter indicates the wavelength of light detected by 
the instrument. 
2.4 Immunofluorescence Microscopy 
2.4.1 Antibodies 
o p19Ink4d (Abcam)(1:100)  
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o p16Ink4a (Santa Cruz Sc-1661)(1:100) 
o pSmad3 (C25A9 Cell Signalling) (1:100) 
o Smad3 (ab28379, Abcam)(1:100) 
o anti-mouse/rabbit/strepdavidin AlexaFluor488/594/647/750/Pacific Blue (life 
technologies)(1:1000) 
o Nanog (Abcam, #Ab14959)(1:300) 
o See FACS antibodies 
2.4.2 Sample preparation 
Cells were reprogrammed in 6 wells on 18 mm circular cover slips  (Fisher Scientific) 
or directly on 6 well Corning plates for colony counting experiments. Cells were fixed in 
4% paraformaldehyde (PFA) in PBS for 10 minutes, then permeabilized in 0.1% Triton 
in PBS for 1-hour at room temperature. Samples were then blocked in 5% normal goat 
serum in PBS for 1 hour, prior to incubation with primary antibodies in blocking 
solution at 4 oC overnight. The next day cells were washed 3 times with PBS, and then 
incubated with secondary antibodies in blocking solution for 1 hour at room 
temperature, followed by 3 washes with PBS. Samples in 6 wells were directly imaged, 
whereas samples on cover slips were mounted on slides (Fisher scientific) using Prolong 
Gold (+/- Dapi) and then imaged. For confocal microscopy, all imaging was performed 
on a Leica TSC SP2 and processed using Adobe Phooshop. For entire well colony and 
cell counting, the images were captured and analyzed using the Celigo S Cell Cytometer 
(Nexcelom). All image processing, including adjustment of gain and range of signal, 
was performed identically for each channel across all samples in any given figure. 
 
2.5 Western Blotting 
 Cells were harvested using Trypsin-EDTA and then washed once with PBS prior 
to lysis with 1X NuPAGE LDS Sample buffer (Life Technologies) (100-250 µl) with 
phosphatase inhibitors (HALT, Life techologies). Lysates were heated to 95oC for 10 
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minutes, followed by sonication of 3 cycles of 15 seconds on a misonix XL2000 
sonicator on setting ~2. Protein concentration was quantified using a Pierce BCA Protein 
Assay Kit (Life technologies) and BSA standard curve. From 1-100 µg lysate was mixed 
with DTT (final concentration 100 mM) and then run in NuPAGE MOPS running buffer 
at 130V for 1.5 hrs on a NuPAGE 10-12% Bis Tris Gel (Life Technologies) using a 
BioRad Mini-PROTEAN electrophoresis machine. Proteins were then transferred to 
0.45 µM Protran nitrocellulose membrane (Sigma Aldrich) on ice at 50V in transfer 
buffer (25 nM Tris, 190 mM glycine, 20% Methanol, pH8.3) for 2-4 hours with a Mini 
Trans-Blot Cell (Bio-Rad). The membrane was then blocked in 5% Skim Milk (Sigma), 
or 5% BSA (for phosphorylated proteins), in TPBS (0.05% Tween in 4000 ml dH20 
containing 121.14 g of Tris base and 438.3 g of NaCl). After blocking, membrane was 
incubated over night at 4 oC with primary antibody in blocking buffer. The following 
day the membrane was washed 3 times with TBST, incubated with HRP conjugated 
secondary antibody for 1 hour, washed 3 times with TBST, and then imaged using the 
ECL based SuperSignal West Pico Chemiluminescent Substrate with X-ray film (Kodak, 
Biomax) and a Konica SRX101A developer.  
2.6 Co-immunoprecipitation  
 Co-immunoprecipitation using nuclear extract lysate was adapted from a 
previously established protocol (Mullen et al., 2011). Samples were first incubated in 
0.5% NP40 in hypotonic lysis buffer (10mM HEPES, 1.5 mM MgCl2, 10 mM KCl) 
with proteinase (cOmplete protease inhibitor cocktail, Roche) and phosphatase inhibitors 
(HALT, Life Technologies), vortexed and left on ice for 5 minutes prior to 
centrifugation at 500 g to pellet nuclei. The pellet was suspended in high salt solution 
(HEPES pH7.9, 1.5mM MgCl2, 0.2mM EDTA, 400mM NaCl, 25% Glycerol) to extract 
nuclear protein.  As a lysate pre-clearing step, Dynabeads-ProteinG (Dynaneads 
ProteinG, Life Technologies, #10003D) were blocked for 1 hour in 2% skim milk in no 
salt-Buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA, 20% Glycerol, 
phosphatase and protease inhibitors), prior to incubation with the nuclear isolated 
samples overnight in IP-buffer (20 mM Hepes, 1.5 mM MgCl2, 0.2 mM EDTA, 20% 
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Glycerol, 100 mM NaCl, protease and phosphates inhibitors). 2 ug of antibody or IgG 
was added to 25 uL blocked Dynabeads for an overnight incubation in IP-buffer. 
Antibody bound beads were then magnetically isolated and added to 200 ug pre-cleared 
lysate for a 3-hour incubation, rotating at 4oC. Beads were then washed 3 times in IP 
buffer and processed for western in LDS buffer as describe above. Antibodies included 
Rb-Smad3 (Abcam, #ab28379), ms-Smad3 (Abcam, #AF9F7), Oct4 (Santa Cruz 
Biotechnology, #sc8628), Sox2 (Santa Cruz Biotechnology, #sc17320), Klf4 (Santa 
Cruz Biotechnology, #sc20691), Dpy30 (Santa Cruz Biotechnology, #sc167677), p300 
(Thermo Scientific, #MS-586-PO), Brg1 (Santa Cruz Biotechnology, #sc17796), Med15 
(Sigma Aldrich, SAB2500761), and IgG (Millipore). 
2.7 Chromatin Immunoprecipitation followed by quantitative PCR 
 Chromatin immunoprecipitation (ChIP) experiments were executed in 3 stages: 
first the cells are fixed in formaldehyde and sonicated, then they are precipitated with 
antibody bound beads, and finally the immunoprecipitated DNA is analyzed using 
quantitative PCR (qPCR).  
2.7.1 Chromatin fixation 
 Cells were grown to 80% confluence in 10 cm dishes, and then fixed for 12 
minutes on a shaker in formaldehyde at 1% final concentration.  Formaldehyde was 
quenched by addition of 1 M glycine (0.125 M final concentration) for 5 minutes 
shaking at room temp. Samples were then washed once in PBS (with protease 
inhibitors), collected with silicon scrapers and centrifuged at 300 g for 5 minutes. Cells 
were re-suspended in PBS with protease inhibitors and aliquot in 107 cell batches (based 
on counts from a sacrificed plate) into eppendorf tubes, centrifuged at 300 g, supernatant 
was removed and pellets were snap frozen on dry ice. 
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2.7.2 Nuclear isolation and sonication 
 A pellet of 107 cells was thawed and re-suspended in lysis buffer (5 mM Pipes 
pH 8, 85 mM KCl, 0.5% NP40) with fresh protease inhibitors (cOmplete protease 
inhibitor cocktail, Roche) and incubated on ice for 20 minutes.  Nuclei were 
subsequently pelleted by centrifugation at 500 g for 10 minutes at 4 oC. Nuclear pellets 
were re-suspended in IP buffer (0.5% SDS, 1% Triton, 2 mM EDTA, 20 mM Tris-HCl 
ph 8, 150 mM NaCl, fresh protease inhibitors), and sonicated in eppendorf tubes as 
follows: 5-8 cycles of 30 second pulses on a BioRuptor Sonicator, on the “high” setting, 
each cycle consisting of 10 minutes of 30 seconds on, followed by 30 seconds off. A 
typical sample of 107 cells from a reprogramming experiment required 8 cycles of 10 
minutes on/off 30 second intervals, over the coarse of 80 minutes. Such conditions 
produced samples with an average band size of ~150 bp, as assessed by DNA gel 
electrophoresis (shown below). After sonication, samples were diluted 2X in IP buffer 
without SDS, to produce a final SDS concentration of 0.25%. Then, 8ug antibody or IgG 
was added to samples for overnight incubation, rotating at 4 oC.  
 
 
Figure 2.1. Sonicated DNA 
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An image of an agarose gel with SybrSafe (25000X) DNA stain to visualize 
examples of fixed and sonicated DNA from 107 cells used for ChIP 
experiments. The ladder is a 1kb plus ladder (Life technologies), whereby 
the 3 bottom bands represent 100, 200 and 300 bp, from bottom to top 
respectively. After the ladder, lanes 1-4 represent 0, 4, 6 and 8 cycles of 
sonication respectively. Sonication for 8 cycles was often used for 
reprogramming experiments, to attain average fragment size of ~150 bp. 
2.7.3 Immunoprecipitation and DNA isolation 
60 ul of Dynabeads-ProteinG (Dynaneads ProteinG, Life Technologies, 
#10003D) were blocked in 0.5% BSA in IP buffer for 1-hour, rotating at 4oC. 
Blocked beads were then magnet extracted and the antibody bound chromatin 
suspensions were added to the pre-blocked bead pellet and rotated at 4oC for 4 
hours. Bead-antibody-chromatin complexes were then magnet isolated, followed 
by a series of washes with increasing stringency to remove non-specific binding 
of Beads to proteins or DNA. Each wash was 5 minutes, rotating at room 
temperature, followed by magnet bead extraction and re-suspension in the next 
wash buffer. The first wash was with IP buffer (150mM NaCl), followed by IP 
buffer with high salt concentration (500mM NaCL), then 1 wash with washing 
buffer (10mM Tris-HCl ph8, 0.25M LiCl, 0.5% NP40, 0.5% Na-Deoxycholate, 
1mM EDTA), followed by 2 washes with TE (10mM Tris, 1mM EDTA). The 
DNA-protein complexes were eluted from the beads by incubation in 100uL 
elution buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl pH8) for 15 minutes at 
65oC. Beads were magnet extracted and DNA containing supernatant collected in 
a new 1.5ml eppendorf tube. Beads were further washed with 150ul TE (with 1% 
SDS), magnet extracted and the suspension was added to the 100uL elution 
buffer containing DNA. The samples were incubated at 65oC overnight to 
reverse crosslink the DNA-protein complexes. The following day, the ChIP’d 
DNA was treated for 2 hours with 5ul (4 units) proteinase K (NEB) at 37oC. 
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DNA was then isolated using Sera-Mag beads as described below, using 2.5X 
bead:DNA suspension ratio (12.8% PEG final concentration). After DNA 
isolation, beads were re-suspended in 30uL ddH2O, magnet extracted, and DNA 
solution was treated with 2ul RNAse A (Life Technologies) at 37oC for 20 
minutes and then stored at -20oC. For qPCR, 0.5µl DNA was used per reaction.  
2.8 RNA sequencing 
 All RNA sequencing was performed in collaboration with Anna Johnsson and 
Sten Linnarsson at the Karolinska Institute in Stockholm, Sweden, according to their 
published works (Islam et al., 2011; Islam et al., 2014). The samples were collected by 
FACS, then 2500 cells were aliquot (500 cells/ul) into PCR strip tubes in PBS 
containing RNAse inhibitor and snap frozen on dry ice prior to shipment to Sweden.  
The cDNA preparation and sequencing was performed as published (Islam et al., 2011; 
Islam et al., 2014). Briefly, universal oligo-dT probes are used to reverse transcribe all 
mRNA. As the MMLV reverse transcriptase reaches the 5’ end of mRNA, it generally 
adds a few oligonucleotides (predominantly cytosines) to the 5’ end of the transcript. 
Thus, this oligoC addition to the endogenous mRNA allows for addition of a barcode on 
the 5’ end of all transcripts through incorporation of barcoded DNA sequence containing 
oligo-GGG on its 3’ end (6bp Barcode-GGG). The barcoded template hybridizes to the 
5’ end of the transcript and as the MMLV encounters this hybrid, it undergoes a 
template switch, and proceeds to extend the newly synthesized cDNA to include the 
barcode. Thus, each prepared sample has a unique barcode, which allows pooling of 
samples for all subsequent library prep, producing a more uniform, unbiased pool of 
libraries.  Recent optimization of the protocol exploits this 5’-CCC strategy to introduce 
unique molecular labels (UMLs), reliant on a large pool of 6-bp barcodes, that when 
added at random to the transcripts prior to amplification, allows for each original 
transcript to be recorded, thereby allowing for a more absolute quantification of each 
transcript by means of molecule counting after sequencing (Islam et al., 2014). After 
reverse transcription and UML incorporation, the full-length cDNA is fragmented and 
further bar-coded with adapters for PCR amplification, in a step known as Tn5 
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transposon mediated fragmentation, or tagmentation.  Amplified libraries are then 
sequenced using an Illumina HiSeq sequencing platform.   
2.9 RNAseq data analysis 
Jon Manning, a resident informatician at our institute, performed all data analysis. RNA-
seq was performed with the single-cell tagged reverse transcription (STRT) platform 
using 500 cells/sample, which had been snap frozen in PBS with RNase inhibitor, then 
processed as previously described (Islam et al., 2012; Islam et al., 2014). The RNAseq 
reads were processed by an automated pipeline as outlined in a recent publication (Islam 
et al., 2014). Counts data, based on both read and molecule counts, were processed with 
the DESeq2 (Version 1.6.3) package of Bioconductor (Love et al., 2014). However we 
found that the processing steps used to produce molecule count data lead to the loss of 
read counts for low-abundance genes, so proceeded with analysis on read count data, 
analogous to standard RNA-seq. 2-3 technical replicates per sample tightly clustered and 
therefore summed across columns prior to further data processing. As per the standard 
DESeq2 protocol, normalized expression estimates were obtained by adjusting columns 
by a size factor corresponding to library size. For read counts, for example, this 
adjustment ranged from 0.57 to 0.71. Data were transformed to log2 scale by use of 
DESeq2's rlog() command, which also minimizes differences at very low count levels. 
The clustering patterns of genes in the two series were assessed based on a matrix of the 
mean of biological replicate samples. Two matrices were constructed containing the 
Cont and +SmCA3 series. The mean of MEF and ES samples were included in both 
series. To reduce noise, genes with background level expression (no mean count >= 2) 
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or low variation (coefficient of variation < 100) in both series were removed from this 
matrix. The matrix was clustered by use of the clara() function in R, which approximates 
the Partitioning About Medoids algorithm. Mean normalized counts of each cross-
classified gene group (with >100 genes) identified in the chord diagram were shown. 
2.10 Quantitative polymerase chain reaction (qPCR) 
The qPCR reactions were performed in 384 well plates, in a 10ul reaction, using the 
LightCycler480 instrument. For a typical qPCR reaction, 10ng of DNA was loaded to 
each well. Depending on experiment, either the SybrGreen (Life Technologies) or the 
universal probe library (UPL) (Roche) system of detection was used, according to 
manufacturers protocol. For each reaction, 0.5uM primers were used.  
 






p19ARF-F GGGTTTTCTTGGTGAAGTTCG 106 Senescence 
p19ARF-R TTGCCCATCATCATCACCT 106 Senescence 
p16Ink4a-F AATCTCCGCGAGGAAAGC 91 Senescence 
p16Ink4a-R GTCTGCAGCGGACTCCAT 91 Senescence 
mouseSmad3-F TCCGTATGAGCTTCGTCAAA 32 
Time course 
reprogramming 
mouseSmad3-R GGTGCTGGTCACTGTCTGTC 32 
Time course 
reprogramming 




Nanog-R GGTTTTGAAACCAGGTCTTAACC 25 
Time course 
reprogramming 





































































































































































Nanog-F1 TTCAGTCCCCGAAGAACCCA NA 
ChIP-qPCR 
H3K4me3 
Dppa4-F1 GCTGGTCCCGGGATAAAACA NA 
ChIP-qPCR 
H3K4me3 




Dppa2-F1 GGCCTCAATCTTGGAACCCT NA 
ChIP-qPCR 
H3K4me3 
Sox2-F1 TTTGTCCGAGACCGAGAAGC NA 
ChIP-qPCR 
H3K4me3 
Esrrb-F1 CCTCTGGCTACCACTACGGA NA 
ChIP-qPCR 
H3K4me3 
Klf2-F1 AAGAGCTCGCACCTAAAGGC NA 
ChIP-qPCR 
H3K4me3 
Utf1-F1 TCCCGGTGACTACGTCTGAT NA 
ChIP-qPCR 
H3K4me3 
Lin28-F1 GCGCACGTTGAACCACTTA NA 
ChIP-qPCR 
H3K4me3 
Lin28b-F1 TTACCTCCGCGGCCTCAT NA 
ChIP-qPCR 
H3K4me3 
Jarid2-F1 CACATCCTTTGGCTTGCAGT NA 
ChIP-qPCR 
H3K4me3 
Tcea3-F1 AGGATCGCCAAAAAGCTGGA NA 
ChIP-qPCR 
H3K4me3 
Nanog-R1 GAGTGATAAGGACACCCGCTT NA 
ChIP-qPCR 
H3K4me3 
Dppa4-R1 CCTCGGGTCCTCTCAGGTTA NA 
ChIP-qPCR 
H3K4me3 
Dppa5a-R1 CCTGTAGCAGGCACTTTTGG NA 
ChIP-qPCR 
H3K4me3 
Dppa2-R1 GCCTTCCTAGTCTGAGACGATT NA 
ChIP-qPCR 
H3K4me3 





Esrrb-R1 CCCCACCCAAAGCCTGAATC NA 
ChIP-qPCR 
H3K4me3 
Klf2-R1 TCCATTTCCCTTCTGGAGGATG NA 
ChIP-qPCR 
H3K4me3 
Utf1-R1 GAAGTAGCTCCGTCTCTCGG NA 
ChIP-qPCR 
H3K4me3 
Lin28-R1 CCTCCCTATCTCCAGGTGGC NA 
ChIP-qPCR 
H3K4me3 
Lin28b-R1 GAGCTCCGTCAGGAAGTGAC NA 
ChIP-qPCR 
H3K4me3 
Jarid2-R1 AGAGCTTTATCGGACGCTGT NA 
ChIP-qPCR 
H3K4me3 
Tcea3-R1 CATAGCTGGGGGAGTCTTGC NA 
ChIP-qPCR 
H3K4me3 
Pou5f1-F1 CGAACCTGGCTAAGCTTCCA NA 
ChIP-qPCR 
H3K4me3 
Sall1-F1 AGAGTCAGGCACAAAGTCCG NA 
ChIP-qPCR 
H3K4me3 
Sall4-F1 GCCCTACATGTGACAAAGGC NA 
ChIP-qPCR 
H3K4me3 
Fbxo15-F1 CCGATGGGCTGTGATCATTT NA 
ChIP-qPCR 
H3K4me3 
Fgf4-F1 GACTACCTGCTGGGCCTCAA NA 
ChIP-qPCR 
H3K4me3 
Pou5f1-R1 CAGTCCAACCTGAGGTCCAC NA 
ChIP-qPCR 
H3K4me3 
Sall1-R1 CAGAGTTTCCGAGCTCCCAG NA 
ChIP-qPCR 
H3K4me3 




Fbxo15-R1 ACCTCATGGAACATCCATCCC NA 
ChIP-qPCR 
H3K4me3 
Fgf4-R1 CCTGCAGGTGGAATCCGATG NA 
ChIP-qPCR 
H3K4me3 
Gdf3-F1 AAGATCCAAGGCCAGACTCC NA 
ChIP-qPCR 
H3K4me3 
Dnmt3l-F1 TTCCCGGGAGACACCTTCTT NA 
ChIP-qPCR 
H3K4me3 
Nodal-F1 ATTGTTTCTCCGTGGGCAGG NA 
ChIP-qPCR 
H3K4me3 
Cbx7-F1 GAGCAGCCTCACCTTCCG NA 
ChIP-qPCR 
H3K4me3 
Cbx1-F1 ACCGATTCCTCTCGGACTCT NA 
ChIP-qPCR 
H3K4me3 
Eras-F1 GTGTAAAGCTCGGGGTTGGA NA 
ChIP-qPCR 
H3K4me3 
Tbx3-F1 GAGGCCAAGGAACTTTGGGA NA 
ChIP-qPCR 
H3K4me3 
Prdm14-F1 GCATGCGCGTAGTAGGTAGT NA 
ChIP-qPCR 
H3K4me3 
Rex1 (Zfp42)-F1 CTGCACTGCACACTCACTCT NA 
ChIP-qPCR 
H3K4me3 
Tcf15-F1 AGTGTCTCCTGCCCTAGGAT NA 
ChIP-qPCR 
H3K4me3 
Zfp296-F1 AAGCGTCAACTCCAAACTGC NA 
ChIP-qPCR 
H3K4me3 





Gdf3-R1 GTTCGTGGGAACCTGCTTCA NA 
ChIP-qPCR 
H3K4me3 
Dnmt3l-R1 CCTGAGGATCTCACAGGATTTCA NA 
ChIP-qPCR 
H3K4me3 
Nodal-R1 CCCACGCCCTACCCTTTTTA NA 
ChIP-qPCR 
H3K4me3 
Cbx7-R1 GCATGGAGCTGTCAGCCATA NA 
ChIP-qPCR 
H3K4me3 
Cbx1-R1 ATTCCTCGGTCTCCGCTCTT NA 
ChIP-qPCR 
H3K4me3 
Eras-R1 TAGGGCCACCGGTCTAACTT NA 
ChIP-qPCR 
H3K4me3 
Tbx3-R1 GAGGGGTCCCCCACTGATTA NA 
ChIP-qPCR 
H3K4me3 
Prdm14-R1 CAGCTCGGTTTCCCACAGAT NA 
ChIP-qPCR 
H3K4me3 
Rex1 (Zfp42)-R1 TTTCTGAATCAGGTCTCAACCA NA 
ChIP-qPCR 
H3K4me3 
Tcf15-R1 TCTGGGCTCCCTCTTTCCTT NA 
ChIP-qPCR 
H3K4me3 
Zfp296-R1 CCGAAGGTCCCGATACTAGC NA 
ChIP-qPCR 
H3K4me3 




Table 2.4. qPCR primers  




2.11 General Molecular Biology 
2.11.1 SeraMag bead isolation of DNA from solution 
 We produce our own SeraMag bead solution, making a product similar to the 
commercially available Agencourt Ampure XP Bead cocktail. The general principle of 
the procedure is based on paramagnetic magnetite beads that are coated in negatively 
charged carboxyl molecules. Upon addition of the hydrophilic crowding molecule PEG 
(polyethylene glycol) along with salt (Na+) to a solution of DNA, the negatively charged 
DNA, shielded by Na+ ions, aggregates and precipitates out of solution, and also binds 
to the carboxyl groups of the beads. When introduced to a magnetic field, the beads are 
drawn out of solution, along with the DNA. Upon removal of PEG, and addition of 
H2O, the DNA is then re-hydrated and goes back into solution. The concentration of 
PEG can be adjusted by adding different volumes of 18% PEG to the initial solution of 
DNA, creating different stringency criteria for DNA-bead interaction, allowing for size 
selection of DNA fragments (Rohland et al, 2012). For example, adding the 18% PEG 
solution to a DNA containing solution at 1.2(PEG-bead solution):1(DNA solution) 
selectively excludes almost all DNA fragments less than 100bp in size, and a further 
reduced ratio of 0.9(PEG-beads):1(DNA) results in exclusion of any DNA fragments 
less than 200bp (Rohland et al, 2012). Thus, the lower the concentration of PEG and 
Na+, the larger the size of DNA fragment precipitated out of the solution.  
 The final Sera-Mag solution is as follows: 0.1% Sera-Mag Magnetic Speed-beads 
(FisherSci, cat.#: 09-981-123), 18% PEG-800 (w/v) (Sigma Aldrich cat.#: 89510), 1M 
NaCl, 10mM Tris-HCl ph8.0, 1mM EDTA, 0.05% Tween 20. The beads are stored at 
4oC, and there efficiency was tested using the Fermentas ladder (Fisher #FERSM1211). 
2.11.2 Gibson assembly cloning protocol 
 Many cloning reactions were performed using the Gibson assembly protocol. 
The method was developed to assemble multiple fragments of DNA into a single linear 
strand in a 1-step reaction (Gibson et al, 2009). DNA fragments with, as small as 15bp, 
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overlapping sequences can be ligated together in the presence of T5 exonuclease 
(Epicentre), Phusion DNA polymerase (New England Biolabs) and Taq DNA ligase 
(New England Biolabs). The 5’ T5 exonuclease chews, or removes, nucleotides from the 
5’ strand of fragments of DNA, creating a single stranded 3’ overhang. When other 
DNA fragments are present, with identical end sequence, they will hybridize 3’ 
overhangs.  The Phusion polymerase can then fill the gaps in the annealed strands, and 
the Taq Ligase seals the nicks.  
 Gibson assembly reactions are initiated by adding equimolar amounts of PCR 
products and the desired plasmid backbone, which has been linearized with a restriction 
enzyme at the site of fragment insertion. Some reactions require the insert fragments to 
be at 3X to 10X the molarity of the plasmid backbone; a parameter that needs to be 
tested experimentally.  The DNA mix is added to 10ul Gibson reaction mix (100mM 
Tris-HCl, 10mM MgCl2, 0.2mM dNTP, 0.5U Phusion Polymerase, 0.16U T5 
exonuclease, stored at -20) and topped up to 20µl. The reaction is incubated at 50oC for 
1hr, and then placed on ice. 3ul of the reaction are transformed into competent bacteria. 
2.11.3 Digestion of plasmid DNA with restriction enzymes 
Restriction enzymes were used to ‘cut and paste’ various segments of DNA between 
plasmids, as well as to check correct orientation of inserts in newly constructed 
plasmids. A typical restriction enzyme reaction consisted of 100-1000 ng DNA, 1ul 
restriction enzyme (New England Biolabs), 1ul appropriate restriction enzyme buffer, 
topped up to 10ul with ddH2O. The reactions are incubated at 37oC for 1 hour unless 
otherwise specified by New England Biolabs. After digestion, the products were run on 
an agarose gel containing SybrSafe (Life technologies) to visualize the bands and/or cut 
out specific bands for cloning purposes. DNA fragment were isolated from agarose gels 




2.11.4 Ligation of DNA fragments 
Both blunt and sticky end DNA fragment ligations were accomplished by adding the 
plasmid backbone to insert at a concentration ratio of 1:3. A typical ligation reaction 
involved 50ηg Vector backbone, 150ηg insert, 1ul T4 DNA ligase (New England 
Biolabs), 1ul T4 Buffer, and then topped up to 10ul with ddH2O. The reaction was either 
stored at 16oC overnight, or incubated at room temperature for 1-hour prior to bacterial 
transformation. 
 
2.11.5 Dephosphorylation of plasmid DNA 
In ligation reactions, it is often necessary to dephosphorylate the plasmid backbone, to 
avoid backbone self-ligation. To accomplish this, plasmids were first digested, and then 
1ul calf intestinal phosphatase (New England Biolabs) was added directly to the reaction 
for 30 minutes at 37oC, prior to purification for ligation reaction. 
2.11.6 Phosphorylation of DNA fragment 
To aid certain ligation reactions, it is beneficial to have phosphorylated DNA inserts and 
dephosphorylated plasmid backbone. To phosphorylate the insert, ~1µg DNA fragments 
or 100µM oligos were added to 1µl T4 Polynucleotide Kinase (New England Biolabs), 
with 1ul T4 PNK Buffer, 1µl 32P ATP (New England Biolabs) topped up to 20ul with 
ddH2O. The reaction was incubated at 37oC for 30 minutes prior to gel extraction or 
cleanup with MinElute reaction cleanup kit (Qiagen) according to manufacturers 
protocol. 
2.11.7 Preparation of cDNA  
RNA was isolated from ~106 cells of 129 MEFs or TNG-MKOS ES or human neonatal 
dermal fibroblasts (HDFn, Life technologies) lines with TRIzol (Life Technologies) 
according to manufacturers instructions.  The RNA was then reverse transcribed to 
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cDNA with the Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) 
(Life Technologies). 1µg of RNA was topped up to 5ul in ddH2O and then added to a 
pre-reaction cocktail of 100uM Oligo dT, 100mM dNTPs to final volume of 10ul, for 
pre-incubation at 65oC for 5 minutes followed by incubation at 37oC indefinitely. The 
pre-incubated sample was then added to 5X M-MLV RT enzyme buffer, 2ul DTT, 1ul 
RNase Inhibitor (Life Technologies), 1ul M-MLV RT and topped up to 20ul in ddH2O 
for incubation at 37oC for 1 hour, followed by 10 minutes at 90oC and then 4oC 
indefinitely. The final product was diluted 10X in ddH2O and then 2ul of that was used 
for PCR reactions. 
2.11.8 Bacterial transformation 
Roughly 10ηg of plasmid DNA was added to 50ul of chemically competent E.coli 
(Commercially available Top10 or Stbl3 lines from Life Technologies, or homemade 
DH5α or Stbl3 competent bacteria) and incubated on ice for 5 minutes, prior to 
incubation at 45oC for 1 minute, followed by 3 minutes on ice. Transformed bacteria 
were then added to 300ul of LB broth, and incubated at 37oC prior to plating on 
antibiotic containing LB agar plates for growth at either 37oC or 30oC overnight. The 
next day colonies were picked with a pipette tip (1000ul Tip) and placed into LB broth 
for bacterial expansion and plasmid DNA extraction. Plasmids were prepped from 5ml 
(mini-prep) or 100-250ml (midi-prep) bacterial broths that were grown in LB broth with 
antibiotic in a shaking incubator at 37oC or 30oC (recombination prone plasmids grown 
at 30oC) and isolated using QIAprep kits (Qiagen) according to manufacturers protocol.  
2.11.9  Sequencing of plasmids 
Plasmids were sequenced by Sanger sequencing with Edinburgh Genomics. Each 
sequencing reaction consisted of 200ng of plasmid, 1.6pmol primer, topped up to a 6ul 
reaction with ddH2O. Primers for sequencing were often the same ones used for cloning, 










Table 2.5. Primers for plasmids sequencing 
A list of primers used to sequence plasmids 
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3: TGFβ signalling inhibition boosts early-intermediate 
reprogramming populations  
3.1 Introduction 
 Soon after the discovery of iPSCs, a large body of work was dedicated to 
screening for small molecules that could boost the extraordinarily inefficient 
reprogramming process. In 2009, 4 independent groups identified that inhibition of 
TGF-β signalling resulted in 20 to 60-fold increase in reprogramming efficiency (Ichida 
et al., 2009a; Li et al., 2010a; Lin et al., 2009; Maherali and Hochedlinger, 2009). Whilst 
the mechanism of reprogramming enhancement by TGF-β inhibition was not clearly 
demonstrated, because of TGF-β’s known roles in development, it was proposed to be in 
part due to an enhanced mesenchymal to epithelial transition (MET) (Lin et al., 2009; 
Maherali and Hochedlinger, 2009). However, several lines of evidence suggested that 
TGF-β inhibitors might contribute to reprogramming enhancement through pathways 
independent of the MET. For example, pre-treatment of fibroblasts with TGF-β 
inhibitor, as a strategy to alleviate mesenchymal signalling, does not have any effect on 
reprogramming, suggesting that the inhibitor acts in cooperation with the 4 
reprogramming factors (Ichida et al., 2009a; Maherali and Hochedlinger, 2009). 
Secondly, when reprogramming epithelial cells, treatment with TGF-β inhibitors results 
in over 6-fold increase in reprogramming efficiency, again suggesting mechanisms 
independent of the MET (Li et al., 2010a). Finally, treatment of partially reprogrammed 
iPSCs, which have already undergone MET, with a short pulse of TGF-β inhibitor 
results in a marked increase in Nanog expression within 10-hours of treatment, driving 
the cells to a stable pluripotent state (Ichida et al., 2009a). It is clear that TGF-β 
inhibition has profound effects on the reprogramming process and that the mechanisms 
of action are, at least in part, independent of the MET.   
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3.1.1 Aims of this chapter 
 The ultimate aim of this chapter is to assess which reprogramming stages are 
most affected by the TGF-β inhibitor. It is possible that TGF-β inhibition might have 
multiple affects at various stages of reprogramming. To assess the impact of TGF-β 
inhibition during reprogramming, a time-course analysis is performed using FACS 
analysis coupled with surface markers and a pluripotency reporter, to observe 
reprogramming progression in the presence or absence of TGF-β inhibitor. 
Immunofluorescence microscopy and qPCR are used to investigate phenotypes in 
further detail at the various stages of reprogramming. Finally, populations of interest are 




3.2.1 TGF-β inhibition boosts reprogramming efficiency  
 The reprogrammable MEFs used for experiments throughout this chapter were 
produced as previously published (Figure 3.1) (Chantzoura E.; Skylaki, in press). 
Briefly, an Sp3 locus targeting vector containing the 4 reprogramming factors c-Myc, 
Klf4, Oct3/4, and Sox2 (MKOS) under a doxycycline (dox) inducible promoter followed 
by ires-mOrange and a CAG-rtTA expression cassette, was transfected into a Nanog-
GFP mES reporter cell line (Chantzoura E.; Skylaki, in press).  The resultant TNG-
MKOS line was then used to produce chimeric embryos via morula aggregation, 
followed by MEF extraction at embryonic stage 12.5 (E12.5). The extracted MEF are a 
mixed batch of transgenic and wt cells, as each embryo has different levels of transgenic 
cell contribution. The percent of transgenic cells was assessed for each batch of MEF by 
monitoring mOrange expression via FACS analysis 48 hours after dox administration 
before freezing down. For reprogramming experiments, the proportion of transgenic 
MEF was adjusted to 5%, surrounded by 95% wt MEF; the previously established 
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optimal reprogramming conditions. Upon dox induction of the 4 reprogramming factors, 
the cells reprogram to an iPSC state within 12 days, as assessed by Nanog-GFP+ 
colonies, at an efficiency of ~1%.  
 
 
Figure 3.1. Transgenic reprogramming system  
Our reprogramming system utilizes an ES line with a Nanog-GFP reporter, 
targeted with a dox inducible MKOS (cMyc, Klf4, Oct4, Sox2) 
reprogramming cassette and an IRES mOrange reporter. The ES line was 
then used for morula aggregation after which embryos were harvested at 
E12.5 and fibroblasts (MEF) were isolated. Transgenic fibroblasts are then 
mixed with wt fibroblasts to have 5% starting transgenic population at the 
outset of reprogramming.   Upon addition of dox, the transgenes MKOS are 
expressed along with the mOrange reporter, allowing the tracking of cells as 
they reprogram to pluripotency. Resultant iPSCs can be distinguished based 
on morphology and expression of the Nanog-GFP reporter. 
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 Previous reports have demonstrated that addition of Vitamin C (VitC) can vastly 
enhance reprogramming efficiency (Chen et al., 2013a; Esteban et al., 2010; Gao et al., 
2015). The mechanism of VitC action during reprogramming was demonstrated to be in 
part due to the up-regulation of the micro RNA (miRNA) cluster 302-367, which is 
thought to enhance the MET (Gao et al., 2015). Because TGF-β inhibition was also 
proposed to promote MET, the TGF-β receptor inhibitor Alki (A83-01) was used to test 
if TGF-β inhibition could enhance reprogramming in the presence of VitC. Alki is an 
inhibitor of TGF-β Type I cell surface receptors, the receptors necessary for downstream 
TGF-β signal transduction (Tojo et al., 2005).  
 The addition of VitC results in over 10-fold increase in total colony numbers, as 
assessed by microscopy, counting colonies based on morphology and the mOrange 
reporter of transgene expression (Figure 3.2A). However, only 65% of colonies 
generated in the presence of VitC activate the endogenous Nanog promoter, as indicated 
by counting reporter Nanog-GFP+ colonies at day 12 of reprogramming. Addition of the 
Alki alone results in a 7-fold increase in total colony numbers, with nearly 100% of the 
colonies expressing Nanog-GFP (Figure 3.2A). Addition of both Alki and VitC results 
in a cumulative affect, whereby a 10-fold increase in reprogramming efficiency is 
observed and ~90% of colonies are Nanog-GFP+ at day 12 (Figure 3.2A).  Because Alki 
was able to boost reprogramming efficiency in the presence of VitC, the remainder of 
reprogramming experiments were performed with VitC to have the most efficient 
reprogramming system and to identify novel mechanisms specific to TGF-β pathway 
inhibition. 
 Observations of colonies reprogramming in the presence of Alki indicated that 
the transgenic cells expanded rapidly in the presence of the inhibitor. To quantify this 
phenotype, FACS analysis was performed to monitor the proportion of mOrange+ 
(transgenic) cells, as compared to mOrange- (wt) cells, in culture throughout 
reprogramming. Absolute value of transgenic and wt cells was extrapolated based on 
total cell counts from each well. In the presence of Alki, transgenic cells rapidly 
proliferated and were twice that of control conditions by day 2 of reprogramming and 
continued to expand more rapidly than the control at day 4 and 6 (Figure 3.2b). 
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Throughout the entire reprogramming process, there were generally less wt cells in the 
dish in the presence of Alki, indicating that the Alki acts in combination with the 
reprogramming factors to boost transgenic cell proliferation.   
 Previous work has hypothesized that TGF-β inhibition boost MET during 
reprogramming. To assess acquisition of epithelial character, FACS analysis was 
performed to quantify E-CADHERIN (E-CAD) levels during reprogramming. In our 
reprogramming system, E-CAD+ cell populations reached over 70% by day 4 of 
reprogramming in either the presence or absence of Alki (Figure 3.2C and D). This 
result indicated that the MET is not a major barrier to reprogramming in this system, and 
also that Alki can increase reprogramming efficiency independent from the enhancement 
of MET. 
 




A) MEFs were reprogrammed with addition of Vitamin C (VitC) or Alki 
alone or in combination. Colonies were counted based on mOrange 
expression (all colonies) and Nanog-GFP+ (successfully reprogrammed) at 
day 12 of reprogramming. B) Total cells were counted and then FACS 
analyzed to extrapolate the numbers of transgenic cells (mOrange+) and wt 
cells (mOrange-) when reprogramming with or without Alki. Results display 
3 independent experiments. C) Quantified FACS analysis results from 3 
independent experiments analysing E-CADHERIN+ transgenic cells 
(mOrange+) during reprogramming. D) Example E-CADHERIN FACS 
analysis experiment, where only mOrange+ cells are displayed and 
quantified for E-CADHERIN expression. Error bars indicate standard 
deviation (s.d.) from 3 independent experiments. *P-value <0.05, **<0.01, 
based on a two-sided t-test. 
 One of the major roadblocks at the onset of reprogramming is the activation of 
senescence (Banito et al., 2009; Kawamura et al., 2009; Li et al., 2009). The rapid 
expansion of cells in the presence of Alki suggested that the TGF-β pathway might 
modulate senescence during the initial stages of reprogramming. Two major branches of 
senescence, p19ARF-p53 and the p16 pathway, were investigated by confocal microscopy 
and qPCR during reprogramming. At day 4 of reprogramming, there is a marked 
increase in P19ARF protein in cells expressing the 4 factors (mOrange+), but not in the 
presence of the Alki (Fig 3.3A and B). By day 8, levels of p19 within the colonies, both 
with and without the Alki, are at very low to undetectable levels (Figure 3.3A). The 
mRNA transcript level was assessed by qPCR, confirming that up-regulation of p19 
expression at day 4 is bypassed in the presence of the Alki (Figure 3.3B). Both protein 
and transcript levels of p16 were very low to undetectable throughout reprogramming 
either in the presence or absence of Alki (Figure 3.3A and B). These results revealed that 
TGF-β signalling impeded the early stages of reprogramming by activating the p19ARF 





Figure 3.3. Reprogramming initiated p19ARF mediated senescence is bypassed with 
addition of the Alki 
A) Confocal microscopy imaging of single colonies (mOrange) stained for 
p19ARF or p16Ink4a at day 4 or 8 of reprogramming. Scale bars are 100µM. B) 
qPCR at day 4 and 8 of reprogramming with or without Alki, normalized to 
Tata Box binding Protein (TBP). Error bars indicate standard deviation (s.d.) 
from 2 independent experiments. *P-value <0.05 based on a two-sided t-test. 
 It is possible that multiple stages of reprogramming are affected by TGF-β 
inhibition. Indeed, while the presence of the inhibitor throughout the entire process has 
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the most profound effect (Figure 3.4), addition for only the first 6 days of 
reprogramming results in half of the effect of addition throughout the entire process. 
Whereas delayed addition of the Alki at day 6 of reprogramming results in over 4-fold 
increase in reprogramming efficiency (Figure 3.4). Those results indicate the inhibitor 
may have affects on multiple stages of reprogramming. 
 
Figure 3.4. Affect of the Alki addition at various stages of reprogramming 
Reprogramming was performed in presence of Alki for the entire experiment 
(16d+Alki), only the first 6 days (6d+, 10d-), or the last 10 days (6d-, 10d+). 
Nanog-GFP+ colonies were counted at day 16. Error bars indicate standard 
deviation (s.d.) from 2 independent experiments.  
 
 To investigate various stages of reprogramming, in addition to the Nanog-GFP 
reporter, the surface markers CD44 and Icam1 can be utilized to monitor reprogramming 
progression (O'Malley et al., 2013). As cells progress from fibroblast to iPSCs, CD44 is 
gradually down regulated, followed by up-regulation of Icam1 and Nanog as cells reach 
a pluripotent state (Figure 3.5). Another indication of successful reprogramming is the 
silencing of transgenes in iPSCs (Hotta and Ellis, 2008; Okita et al., 2007), which can be 






Figure 3.5. Live-cell imaging with reprogramming stage specific surface markers 
Confocal microscopy live imaging of colonies (mOrange+) undergoing 
reprogramming. Fluorophore conjugated antibodies were used to visualize 
Icam1 and CD44, in conjunction with the Nanog-GFP reporter on a pair of 
colonies undergoing reprogramming. Scale bars are 100 µm. 
 Reprogramming progression was monitored by FACS analysis with CD44, 
ICAM1 and Nanog-GFP over a 16 day reprogramming experiment. In the presence of 
Alki, there is a clear acceleration of CD44 down regulation at day 8 of reprogramming. 
Furthermore, ICAM1 up regulation and Nanog-GFP activation is apparent by day 8 of 
reprogramming; 2 to 4 days before the control experiment (Figure 3.6).  At the final time 
points of reprogramming, at day 12 and 16, there remain populations of cells and 
colonies that express mOrange but are unable to up regulate Icam1 or Nanog, stuck at 
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intermediate stages of reprogramming. In the Alki condition, the stuck populations are 
noticeably fewer, indicating that roadblocks are overcome in the presence of the 
inhibitor (Figure 3.6). 
   
 
 
Figure 3.6. FACS analyses with CD44 and ICAM1 reprogramming with or without 
Alki. 
A reprogramming time course FACS analyses of CD44 and ICAM1 
staining, displaying all transgenic cells (mOrange+). Nanog-GFP positive 
cells are demarked by green dots, while all other transgenic cells are in red.  
 
 Because the reprogramming populations behave so differently in the presence of 
the Alki, it is hard to distinguish which populations of cells are most affected by the 
inhibitor. To identify reprogramming populations targeted by the inhibitor, cells were 
reprogrammed in the presence or absence of the Alki for 10 days and then sub-
populations were sorted, based on CD44/ICAM1/Nanog-GFP expression, into media 
without Alki to assess there ability to form colonies after a further 10 days of 
reprogramming (Figure 3.7). Cells that were at intermediate stages of reprogramming, 
CD44-/ICAM1-/NANOG-GFP+ (2N+) and CD44-/ICAM1+/NANOG-GFP- (3N-), 
showed over 2-fold increase in reprogramming efficiency when sorted from 
reprogramming in the presence of the Alki for the first 10 days. Interestingly, the early 
CD44+/ICAM1-/Nanog-GFP- populations coming from Alki conditions were less 
 
 72 
efficient at reprogramming, perhaps as a result of sorting at such a late time-point of 
reprogramming (Figure 3.7). 
 
Figure 3.7. Alki affects intermediate reprogramming populations 
Day 10 reprogramming populations were sorted based on CD44, ICAM1 
and Nanog-GFP (N+/-) expression profiles. Population 1 (CD44+/ICAM1-), 
2 (CD44-, ICAM1-), and 3 (CD44-/ICAM1+) represent reprogramming 
populations sorted. Each population was also sorted based on whether or not 
it expressed Nanog-GFP (N+ or N-). 10 days after sorting, Nanog-GFP+ 
colonies were counted and displayed in graph on the right. Error bars 
indicate standard deviation (s.d.) from 3 independent experiments. *P-value 





3.3.1 TGF-β signalling inhibition acts independent of the mesenchymal to 
epithelial transition during reprogramming 
 The early stages of reprogramming are characterized by a mesenchymal to 
epithelial transition (MET), as fibroblasts convert to a pluripotent state (Li et al., 2010a; 
Samavarchi-Tehrani et al., 2010). E-cad expression is a hallmark of the MET, and is 
necessary for reprogramming as a crucial component of the stem cell epithelial program 
(Redmer et al., 2011). Because the TGF-β signalling pathway is known to be involved in 
the specification of mesenchyme during development (Xu et al., 2009), it was proposed 
that TGF-β inhibition accelerates reprogramming by alleviating mesenchymal signalling 
and boosting the transition to epithelial character (Polo and Hochedlinger, 2010).  
However, results presented in figure 3.2 demonstrate that E-cad expression is not 
significantly affected by TGF-β inhibition in our reprogramming system. Furthermore, 
addition of the Alki at d6, post MET, or sorting cell populations beyond MET coming 
from Alki condition, demonstrated enhanced reprogramming efficiency. These data 
suggested that the major mechanism by which TGF-β inhibition boosts reprogramming 
is not the acquisition of epithelial character.    
 Treatment of epithelial cells in culture with TGF-β ligands, can convert them to a 
mesenchymal phenotype (Miettinen et al., 1994; Piek et al., 1999; Valcourt et al., 2005).  
During reprogramming, there are TGF-β ligands in the culture, sourced from both the 
fibroblasts themselves, and present in serum of the media (Chin et al., 2001; Li et al., 
2010b; Schmid et al., 1998). Therefore Alki should have shown some sort of MET 
acceleration during reprogramming. However, probably the over-expression of Klf4, a 
master transcription factor of the epithelial program (Garrett-Sinha et al., 1996), 
overrides any effect of TGF-β ligands in culture, even in the absence of Alki. The 
finding that E-cad is expressed at maximal levels by day 4 of reprogramming also 
suggests that the MET is not a substantial barrier to overcome on route to pluripotency 
in our reprogramming system. Our lab previously demonstrated that most polycystronic 
reprogramming vectors commonly used in the research field contain a truncated form of 
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Klf4, missing the first 9 aa of full length Klf4 (Chantzoura E.; Skylaki, in press). With 
such polycystronic reprogramming vectors, MET seems to be a roadblock for 
reprogramming. However, with a polycystronic reprogramming vector with full length 
Klf4, MET is not a roadblock and thus, any affect of the Alki on MET might be subtle 
during such an efficient process.  
 
3.3.2 TGF-β inhibition enables bypassing of senescence at onset of 
reprogramming 
  During reprogramming the over expression of the oncogene c-Myc, and 
to a lesser extent Oct4 and Sox2, elicits a senescence response in MEF that includes the 
up regulation of p19ARF, p16Ink4a and p53 (Banito et al., 2009; Hong et al., 2009; 
Kawamura et al., 2009; Li et al., 2009). Senescence, by definition, is a cellular program 
characterized by the irreversible arrest of the cell cycle, and is therefore a major barrier 
to successful reprogramming (Kawamura et al., 2009; Li et al., 2009). In parallel, 
extensive studies have provided strong links between TGF-β and senescence pathways 
in various contexts (Cordenonsi et al., 2003; Senturk et al., 2010). Throughout 
reprogramming, cells would be exposed to TGF-β, as it is present in the serum of media 
and is produced by fibroblasts (Chin et al., 2001; Li et al., 2010b; Schmid et al., 1998).  
Interestingly, the p19ARF locus is a direct target of SMAD2/3 and is activated upon TGF-
β stimulation of MEFs (Zheng et al., 2010). Treating MEFs with inhibitors of TGF-β 
receptors, as well as knockdown of Smad2/3, impedes TGF-β mediated p19ARF 
induction (Zheng et al., 2010). In addition, TGF-β receptors activate the p38MAPK/NF-
κB pathway, which initiates a senescence response in fibroblasts (Freund et al., 2011). 
Blocking of TGF-β signalling during reprogramming possibly alleviates p38MAPK-
initiated senescence, and certainly bypasses p19ARF activation, as demonstrated in this 
thesis. 
 When c-Myc alone is over-expressed in MEF, there is a marked increase in 
proliferation, and some MEF transform to an immortalized self-renewing state, termed 
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transformation (Greenberg et al., 1999; Qi et al., 2004b). P19ARF directly mediates C-
MYC activity, binding to C-MYC and inhibiting its ability to activate transcription of 
target loci. Over-expression of P19ARF results in a failure of C-MYC to induce 
proliferation and transformation of MEF, in a process that is independent of p53 (Qi et 
al., 2004b). In the reprogramming context, it is plausible that p19ARF up regulation not 
only activates the senescence program, but also inhibits the exogenous C-MYC activity. 
It would be interesting to test if p19ARF knockdown, or Alki treatment, can enhance 
reprogramming in absence of c-Myc expression. Interestingly, when reprogramming 
with p19ARF and p16Ink4a knockdown, the increase in reprogramming efficiency was far 
greater in 4-factor than in 3-factor reprogramming system without c-Myc (Li et al., 
2009). The same experiment was not performed with p19ARF knockdown alone, but 
those findings suggest there may be P19ARF direct inhibition of C-MYC activity during 
reprogramming.  
3.4 The Alki accelerates transition from a partially reprogrammed to 
a pluripotent state 
 Reprogramming is a step-wise process, with cells gradually overcoming barriers, 
and establishing the pluripotency transcriptional network (Ruetz and Kaji, 2014). To 
assess reprogramming progression, cell surface markers and endogenous pluripotency 
reporters are used. One of the most stringent pluripotency markers is Nanog, which is 
activated relatively late in the reprogramming process, and strongly correlates with a 
stable pluripotent state (Buganim et al., 2012; O'Malley et al., 2013). In addition, the 
surface markers CD44 and Icam1 demarcate the various stages of reprogramming, 
allowing for precise monitoring of reprogramming progression (Lujan et al., 2015; 
O'Malley et al., 2013; Zunder et al., 2015). Fibroblasts express high levels of CD44 and 
a broad range of ICAM1 expression. As populations transition to a partially 
reprogrammed state, they down regulate Icam1 and CD44 expression, to a double 
negative intermediate, partially reprogrammed state. Eventually, the intermediate 
populations begin to activate Icam1 expression in conjunction with Nanog expression. 
The end-stage iPSC profile is that of low CD44, high Icam1 and high Nanog expression 
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(O'Malley et al., 2013). With staining for CD44, ICAM1, and a Nanog-GFP endogenous 
reporter, I investigated the affect of Alki on various reprogramming populations. The 
results highlighted the inhibitor’s role in not only boosting efficiency, but also 
acceleration of reprogramming process. By day 8 of reprogramming, the double negative 
CD44/ICAM1 intermediate stage is rapidly produced in the presence of inhibitor, and 
Nanog-GFP expression is observed 4 days earlier in the process.  
 In addition, the sorting experiments revealed that intermediate populations that 
came from Alki conditions were more likely to generate Nanog-GFP+ colonies even if 
they have the same CD44/ICAM1/Nanog-GFP marker expression, suggesting those 
populations had unique characteristics generated by the presence of the Alki. Those 
results demonstrate the affects of TGF-β inhibition at intermediate stages of 
reprogramming, beyond MET and senescence. 
 Previous work has highlighted a role for Alki in producing a more homogenous 
pluripotent state, whereby treatment of mouse ES cells results in a high Nanog 
expression (Galvin-Burgess et al., 2013). Treatment of ES cells with the Alki results in 
activation of the BMP pathway and associated response genes, such as Id proteins, to 
become up regulated and drive pluripotency gene expression (Galvin-Burgess et al., 
2013). In the reprogramming context, a short pulse with TGF-β inhibitor results in a 
marked increase in NANOG protein levels within 12 hours of treatment, and drives 
partially reprogrammed cells to pluripotency (Ichida et al., 2009a). The elevation of 
BMP signalling in the presence of Alki could be a potential mechanism through which 
Alki might enhance reprogramming populations transitioning to a pluripotent state. 
Indeed, it has previously been demonstrated that addition of BMPs to culture can boost 
reprogramming efficiency (Samavarchi-Tehrani et al., 2010). Future work could explore 




4: Identifying the underlying mechanism of TGF-β 
inhibition during reprogramming  
 
4.1 Introduction 
 TGF-β inhibition has profound effects on reprogramming, increasing the overall 
efficiency over 10-fold and vastly accelerating the transition to a pluripotent state. TGF-
β receptors target a number of downstream pathways including p38(MAPK), 
PI3K(Akt1/2), RhoA, Ras(ERK), TAK1 and Smad2/3 (Shi and Massague, 2003b; 
Zhang, 2009). Upon TGF-β ligands binding receptors, the receptors dimerize and the 
cytosolic kinase domains become active (Shi and Massague, 2003a) (Figure 4.1). The 
most well-established and extensively characterized target of TGF-β receptor activity is 
the phosphorylation and activation of Smad2/3 transcription factors (Figure 4.1). Indeed, 
Smad2/3 are core players in TGF-β downstream signalling, whereby knockout of either 
protein greatly reduces the TGF-β transcriptional response (Kretschmer et al., 2003; 
Lakos et al., 2004; Wakabayashi et al., 2011). This chapter tests the hypothesis that 
dampening Smad2/3 signalling is the primary downstream mechanism of action of the 






Figure 4.1. Overview of TGF-β signalling and associated inhibitors 
TGF-β signalling is initiated by ligands binding to Type II membrane 
receptor dimers, which then form a tetramer with and activate 
(phosphorylate) Type I receptor dimers. Type I receptors then phosphorylate 
and activate downstream signalling pathways, including PI3K, RhoA, Ras, 
Tak1 and Smad2/3.  The Alki works by inhibiting the Type I receptor kinase 
domain, thereby inhibiting all Alk receptor downstream signalling. The 
specific inhibitor of Smad3 (SIS3) inhibits only the Smad3 signalling 
pathway. 
4.1.1 Aims of this chapter 
 The ultimate aim of this chapter is to assess the role of Smad2/3 during 
reprogramming. A specific inhibitor of Smad3 (SIS3) is used to assess Smad3’s 
importance for reprogramming progression. Smad3 inhibition phenotypes are explored 
with a combination of immunofluorescence, FACS analysis, western blotting and image 
cytometry. As a complementary approach, over-expression of constitutively active 
Smad3 (Smad3CA) and Smad2 (Smad2CA) are performed to further explore their roles 
during reprogramming. Finally, time course RNA sequencing was performed to assess 
transcription dynamics throughout reprogramming in the presence of Smad2CA/3CA. 
 
4.2 Results 
4.2.1 Inhibition of Smad3 impedes reprogramming 
One of the most extensively characterized and primary targets of TGF-β 
receptors are the Smad2/3 transcription factors.  To test if lack of the Smad2/3 mediated 
signalling is the main cause of the enhanced reprogramming phenotype by Alki, I added 
a specific inhibitor of Smad3 (SIS3) during reprogramming, and evaluated if it 
recapitulated the Alki results (Figures 4.1 and 4.2). Strikingly, and unexpectedly, the 
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presence of SIS3 during reprogramming almost completely abolished successful 
reprogramming (Figure 4.2). Furthermore, addition of SIS3 in the presence of Alki 
eliminates the positive affects of the Alki, again reducing reprogramming efficiency 
(Figure 4.2).  The SIS3 did not have a general effect on fibroblast survival, as indicated 
by the presence of over 50 partially reprogrammed colonies at day 12 (Figure 4.2 and 
4.3A), and counting of transgenic (mOrange+) and wt (mOrange-) cells at day 8 of 
reprogramming using FACS analysis (Figure 4.3B). There were similar levels of 
transgenic cells in control and SIS3 treatment at day 8 of reprogramming, while there 
were almost 2-fold more wt cells in the presence of SIS3, indicating the inhibitor did not 




Figure 4.2. Specific inhibitor of Smad3 blocks reprogramming 
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Reprogramming was performed with addition of Alki, or a specific inhibitor 
of Smad3 (SIS3), alone or in combination. Colonies were counted at day 12 
of reprogramming. Error bars indicate standard deviation (s.d.) from 3 
independent experiments with 2 experimental replicates. *P-value <0.05 
based on a two-sided t-test. 
 
 
 Figure 4.3. SIS3 blocks reprogramming independent of cell viability 
A) Example colonies at day 12 of reprogramming. Scale bar 100µM. B) Cell counts 
based on FACS analysis from day 8 of reprogramming. Total cell were counted from 
1 well of a 6-well reprogramming experiment, then FACS analyzed to enumerate 
transgenic (mOrange+) and wt (mOrange-) cells in the control (cont) and SIS3 
treatments. Results show 2 independent experiments, with 2 experimental replicates. 
Error bars represent standard deviation.  
To assess at what stage of reprogramming cells failed in the presence of SIS3, FACS 
analysis with CD44 and ICAM1 was performed from day 6-14 of reprogramming. By 
day 10 of reprogramming, a clear difference in populations emerged, as SIS3 
reprogramming experiments stalled at the intermediate (CD44-/ICAM1-) stage of 
reprogramming, while the control conditions had started to up regulate ICAM1 and the 
Alki condition were also starting to express Nanog-GFP (Figure 4.4). By day 12 only 
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12% of cells made the final stage in the presence of SIS3, as compared to 53% and 68% 
of control and Alki conditions respectively (Figure 4.4). 
  
Figure 4.4. SIS3 stalls reprogramming at intermediate stage 
FACS analysis of transgenic cells stained with CD44 and ICAM1 surface 
markers performed over a reprogramming experiment. Green dots represent 
Nanog-GFP+ cells, with red dots representing the rest of the transgenic 
(mOrange+) cells. 
 
The SIS3 treatment results suggested that active Smad3 might be important for 
reprogramming, but this idea contradicted the effect of Alki, which was supposed to 
block SMAD2/3 phosphorylation. To confirm the amount of activated Smad3 during 
reprogramming in the presence and absence of the inhibitors, immunofluorenece was 
performed with a c-terminal phosphorylated-SMAD3 (pSMAD3) specific antibody.  At 
day 4 and 8 of reprogramming, low levels of pSMAD3 were detected in the untreated 
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reprogramming context (Figure 4.5 and 4.6). The colonies in +SIS3 culture had low to 
undetectable levels of pSmad3, as expected. By day 12 of reprogramming, pSmad3 
levels are at low to undetectable levels (Figure 4.7). In contrast, surprisingly, there was 
an apparent increase of pSmad3 in the presence of the Alki (Figure 4.5 and 4.6). 
Interestingly, pSmad3-high cells co-localized in regions of the colony with higher levels 
of Nanog-GFP expression in the absence of the inhibitors and presence of Alki (Figure 
4.6).  
 
Figure 4.5. Active Smad3 (pSmad3) levels at day 4 of reprogramming 
Confocal microscopy at day 4 of reprogramming staining for pSMAD3 and 




Figure 4.6. pSmad3 levels in colonies at day 8 of reprogramming 
Confocal microscopy at day 8 of reprogramming with staining for pSMAD3, 
E-CADHERIN, and total SMAD3 in combination with a Nanog-GFP 






 Figure 4.7. Day 12 reprogramming colonies have low levels of pSmad3 
Confocal microscopy at day 12 of reprogramming with staining for 
pSMAD3, E-CADHERIN and SMAD3 in combination with the Nanog-GFP 




 To quantify pSmad3 levels during reprogramming in the presence of Alki, a 
celigo imaging cytometer was used to image entire 6 well plates stained for pSMAD3 at 
day 4 of reprogramming. Day 4 was chosen because cells are less dense at this stage of 
reprogramming, allowing for quantification of single cell fluorescence characteristics. 
Quantifying an entire well, the total mOrange+ cells were first enumerated and then 
assessed for pSMAD3 levels in cells. A cut off was set such that only cells with 
punctuated, high nuclear levels of pSMAD3 were counted as positive (Figure 4.8A). Of 
all mOrange+ cells, ~40% were pSmad3+ at day 4 of reprogramming in the absence of 
inhibitors, whereas in the presence of the Alki, ~60% were pSmad3+ (Figure 4.8B). 
Another commonly used TGF-β receptor inhibitor SB431542 (SB43) exhibited similar 
results, producing higher levels of pSmad3 in cells undergoing reprogramming at day 4 
(Figure 4.8B).  While these data contradicted what the inhibitors were supposed to do, I 
could confirm that these inhibitors blocked SMAD2/3 phosphorylation upon 1-hour 
TGF-β treatment as expected (Figure 4.8C). Similarly, when wt MEFs were cultured in 
the presence of the inhibitors for 24 hours, I could observe decreased numbers of MEFs 
with nuclear p-SMAD3 staining, compared to no inhibitor treatment (Fig 4.8D). 
However, when the culture period was extended to 4 days, I could again observe 
increased pSMAD2/3 in the presence of either Alki or SB with wt MEFs, similarly to 
the reprogramming context (4.8E). These results indicated that increased pSMAD2/3 
levels in the presence of Alki were not specific to the reprogramming context, but rather 
dependent on the prolonged culture time in the presence of inhibitors. The TGF-β 
signalling pathway has auto-regulatory mechanisms, and the chemical inhibitors may not 
100% block the receptor kinase activity (Itoh et al., 1998; Shi and Massague, 2003a). A 
small leak of the receptor kinase activity may be skewing the regulatory mechanisms, 






Figure 4.8. Quantifying pSmad3 during reprogramming 
A) Celigo imaging cytometer analysis of 6-well plates at day 4 of 
reprogramming with staining for pSMAD3 and the mOrange reporter for 
identification of transgene expressing cells. Cells with punctate nuclear 
staining were considered positive for pSMAD3, as indicated by the lower 
left panels with cells outlines in blue.   B) Graph displays the percent of 
transgenic cells (mOrange+) positive for pSMAD3 staining, in 3 
independent experiments. C) Western Blot displaying pSMAD2/3 levels in 
MEF treated for 1-hour with TGF-β ligand in combination with Alki (A83-
01) or SB43 (SB431542). D) Percent of transgenic cells with nuclear 
pSMAD3 staining after 24-hour treatment with Alki or SB43. E) Western 
blot showing pSMAD2/3 after 4-day treatment of MEF with Alki or SB43. 
Error bars indicate standard deviation (s.d.) from 3 independent experiments 





4.2.2  Constitutively active Smad2/3 boost reprogramming  
The results above suggest that active Smad2/3 is concordant with successful 
reprogramming. To assess if Smad2/3 actively support the reprogramming process, 
constitutively active (CA) Smad2CA and Smad3CA were over expressed during 
reprogramming. The pMXs retroviral packaging system (Kitamura et al., 2003) was 
used to infect and over express Smad2CA/3CA constructs in our TNG-MKOS MEF 
reprogramming system.  The engineered Smad2CA/3CA constructs have c-terminal base 
substitutions producing phosphomimetic pepetides, mimicking their phosphorylated and 
active state (Chipuk et al., 2002; Funaba and Mathews, 2000). Using the TNG-MKOS 
MEF reprogramming system, cells were infected with Smad2CA/3CA or control blue 
fluorescent protein (BFP) retroviral particles and reprogrammed for 12 days. The 
infection with retroviral particles is mildly toxic to the cells, as can been seen by a 
reduced reprogramming efficiency in our control condition as compared to previous 
reprogramming experiments (compare figure 4.2 and 4.9a). There was an over 6-fold 
increase in Nanog-GFP+ colonies in the presence of Smad2CA or Smad3CA (Figure 
4.9A). When expressed together, Smad2CA/3CA demonstrated a 10-fold increase in 
reprogramming efficiency, perhaps as a result of the cooperative nature of Smad2/3 
action (Figure 4.9A). Time course FACS analysis revealed that Nanog-GFP was 
activated more robustly in the presence of Smad2CA/3CA, while the onset of E-cadherin 





Figure 4.9. Constitutive active Smad2/3 enhance reprogramming  
A) Total Nanog-GFP+ colonies at day 12 of reprogramming with various 
treatments. TNG-MKOS MEF were reprogrammed and ‘topped-up’ with 
retroviral mediated over-expression of constitutively active Smad2/3 
(Sm2CA/Sm3CA) or blue fluorescent protein (BFP; control) B/C) FACS 
analysis quantifying Nanog-GFP/E-CADHERIN (E-CAD) expression in 
transgenic (mOrange+) cells during reprogramming. Error bars indicate 
standard deviation (s.d.) from 3 independent experiments with 2 
experimental replicates. *P-value <0.05 based on a two-sided t-test. 
 
 To investigate the dynamics of reprogramming progression in the presence of 
Smad2CA/3CA, a time-course FACS analysis was performed with the CD44 and ICAM1 
surface markers (Figure 4.10). Reprogramming with the 4 Yamanaka factors, plus a 
combination of Smad2CA, Smad3CA or both expressed together resulted in a similar 
accelerated reprogramming phenotype. Reprogramming progressed with marked 
acceleration apparent at day 8 of reprogramming as the intermediate CD44low, ICAM1low 
stage is achieved rapidly when Smad2CA/3CA are over-expressed (Figure 4.10 days 4-
8). Nanog-GFP expression was observed ~5 days earlier with Smad2CA/3CA as 
compared to the control (Day 10 compared to 15, Figure 4.10), in parallel with 
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accelerated ICAM1 up regulation (Figure 4.10 days 8-12). 
 
Figure 4.10. Reprogramming progression with Smad2CA/3CA 
FACS analysis was performed with staining for ICAM1 and CD44 over a 
15-day reprogramming experiment with over-expression of Smad3CA or 
Smad2CA or both, compared to control (BFP). FACS plots show only 
transgenic (mOrange+) cells, green dots indicate Nanog-GFP positive cells.  
4.2.3 RNA sequencing reveals global acceleration and bypass of aberrant 
transcriptional programs when reprogramming with addition of Smad3CA 
Global gene expression profiling was performed at day 3, 6, 8, and 10, 
comparing reprogramming with Smad3CA and a vector expressing blue fluorescent 
protein (BFP; control).  A list of pluripotency-associated genes was investigated across 
all time-points of reprogramming, revealing very little expressional changes between 
Smad3CA and control during the first 8 days of reprogramming. However, by day 10, 
almost every pluripotency gene assessed was expressed higher in the presence of 
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Smad3CA than control, as confirmed by gene set enrichment analysis (Figure 4.11A and 
B) 
 
Figure 4.11. Pluripotency gene expression during reprogramming with addition of 
Smad3CA  
Global gene expression was assessed with RNA sequencing over a 10-day 
reprogramming experiment. A) Expression patters of all genes (grey dots) 
comparing control and Smad3CA samples on day 3, 6, 8, 10 of 
reprogramming. A panel of 30 pluripotency genes are highlighted with 
various coloured shapes showing their expression profiles during 
reprogramming, demonstrating a marked increase in expression of almost all 
genes in the presence of Smad3CA at day 10. The dashed lines indicate 2-
fold differences between the samples.  B) Gene Set Enrichment Analysis 
(GSEA) for the pluripotency genes listed in (A). ES; Enrichment Score, 





To further explore the contribution of Smad3CA during reprogramming we performed 
gene-clustering analysis, grouping 3750 genes with above background expression levels 
(mean count >= 2) and low variation (coefficient of variation < 100) into 8 distinct 
expression patterns over the course of the reprogramming experiment. Seven clusters in 
control and +Smad3CA sample series were very similar, including groups down-
regulated by day 3 (Dw), transiently up-regulated at day 3 (D3Up), transiently up-
regulated at day 8 (D8Up), highly (D10Up) or slightly (D10sUp) up-regulated at day 10 
but low expression in ESCs, expected to be up-regulated after day 10 (Up), and finally a 
down-then-up cluster (DwUp) (Figures 4.12A). Additionally, the control series had a 
cluster of transiently up-regulated genes on day 6 (D6Up), and +Smad3CA series had a 
group of genes up-regulated earlier than the Up genes (eUp) (Figures 4.12A). To 
compare trends across the Smad3CA and control treatments, a cord diagram was 
produced to display where genes within given clusters were located in the other 
treatment. The cord diagram revealed that genes in Dw, D3Up, Up, and DwUp clusters 
were very similar between control and Smad3CA samples (Figure 4.12B). However, 
several differences emerged, including with the control D8Up genes, which were 
classified into Smad3CA D10sUp genes (108 genes), indicating this aberrant up-
regulation was minimized in the presence of Smad3CA (Figure 4.12C). About 24% and 
45% of control D10Up genes were cross-classified into D8Up (124 genes) or D10sUp 
(233 genes) Smad3CA clusters, where the peak of the transient up-regulations in 
Smad3CA were accelerated to day 8 or bypassed altogether (Figure 4.12D and E). Most 
of control D10sUp genes fell into Smad3CA D10Up cluster (102 genes) (Figure 4.12F). 
Finally, almost all genes that belonged to eUp, a unique cluster of early activated genes 
in the Smad3CA series, were classified in the late-activated control Up cluster (120 
genes) (Figure 4.12G). These results demonstrate a swifter and more efficient transition 





Figure 4.12. Gene expression clustering analysis 
A) Gene expression categories clustered by similar gene expression changes 
during reprogramming with (+Smad3CA) and without (Cont) Smad3CA over 
expression. The blue and red lines represent mean values of each cluster. 
Numbers of genes in each category were indicated. Note values of ESC 
samples (ES) are included in the analysis to incorporate directions of gene 
expression changes after day 10. B) A chord diagram to compare 
distribution of genes classified in each category in control (left) and 
+Smad3CA (right) reprogramming. Asterisks indicate cross-classified gene 
groups with more than 100 genes.  C-G) Expression patterns of the cross-
classified gene groups highlighted in (B) in control (blue) and +Smad3CA 




4.3.1 Smad2/3 are active during reprogramming 
 Upon TGF-β ligand binding receptors, the intracellular kinase domains of the 
receptors are activated. While Smad2/3 are primary targets of TGF-β receptor kinase 
activity, many other cytosolic proteins are phosphorylated and regulated by the receptors 
(Massague, 2012; Shi and Massague, 2003a). A specific inhibitor of Smad3 (SIS3) was 
used to assess if blockage of the TGF-β-Smad3 pathway was the major cause of the 
reprogramming enhancement by the Alki. Surprisingly the SIS3 phenotype suggested 
that Smad3 activity might be required for successful reprogramming. MEF did not 
simply die or senesce in the presence of the inhibitor, but appeared to be stuck at an 
intermediate stage of reprogramming. Subsequent work demonstrated that Smad2/3 are 
phosphorylated and active during reprogramming, and are active in cells with Nanog-
GFP expression as reprogramming proceeds. Those results suggest that Smad2/3 might 
be actively involved in establishing pluripotency network gene activation. Previous work 
has described roles for Smad2/3 in the specification of various lineages during 
development, with extensive work demonstrating a role for Smad2/3 during 
mesenchyme differentiation (Medici et al., 2011; Miettinen et al., 1994; Piek et al., 
1999; Valcourt et al., 2005; Xu et al., 2009). For that reason it was surprising to identify 
that Smad2/3 actively benefit the reversion of fibroblasts to a pluripotent state. However, 
a hallmark of Smad2/3 signalling is the context dependency, whereby different cellular 
states direct Smad2/3 transcriptional responses. In the presence of 4 core pluripotency 
genes being over-expressed, it is not entirely surprising that Smad2/3 would not perform 
the same role as they do in the maintenance of mesenchymal tissue.  
4.3.2 Alki treatment results in increased Smad2/3 activity during reprogramming 
 Treatment with Alki during reprogramming was expected to decrease Smad2/3 
mediated signalling during reprogramming. Conversely, Alki did not reduce, but rather 
increased, pSMAD2/3 levels. The TGF-β signalling pathway is auto-regulatory whereby 
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activation of Smad2/3 is a transient response and high levels of activation results in a 
dampening of TGF-β cell responsiveness, through modulation of receptor activity or 
ligand expression (Itoh et al., 1998; Shi and Massague, 2003a). For example, within 
minutes of TGF-β stimulation, SMAD2/3 bind the promoter and activate transcription of 
the negative regulator Smad7, which directly interacts with TGF-β receptors and inhibits 
their kinase activity (Kavsak et al., 2000; Suzuki et al., 2002). SMAD7 also induces 
TGF-β receptor ubiquitination and subsequent degradation (Ebisawa et al., 2001; 
Kavsak et al., 2000). Similarly another TGF-β negative regulator, SnoN, is up regulated 
within 2-hours of TGF-β stimulation. SNON can directly bind SMAD2/4 and act as a 
transcriptional repressor (Luo et al., 1999). Thus, inhibiting TGF-β receptors would also 
alleviate the negative feedback loops of the pathway. It is possible that prolonged 
exposure to the Alki during reprogramming, and corresponding extended absence of 
negative feedback loops, primes cells for an eventual increased TGF-β-Smad2/3 
response by stabilising TGF-β receptors on the membrane. Indeed results in this chapter 
demonstrate that a 1-hour treatment of MEF with Alki results in reduced pSmad2/3, and 
it is only after a prolonged 4-day treatment that an increase in phophorylation levels was 
observed.  
   
4.3.3 Constitutive active Smad2/3 boost reprogramming 
Expression of Smad2CA and Smad3CA demonstrated that constitutively active versions 
of those proteins not only boost overall reprogramming efficiency, but also accelerate 
the activation of the pluripotency network and bypass some aberrant transcriptional 
programs. Many studies have characterized a role for Smad2/3 in maintenance of 
pluripotency, and directly regulating the Nanog locus in stem cells (Gaarenstroom and 
Hill, 2014; Sakaki-Yumoto et al., 2013; Xu et al., 2008). Smad2/3 play pivotal roles in 
maintenance of mouse epiblast like stem cells (EpiSCs) and the transcriptionally similar 
human ES cells, whereby inhibition of TGF-β signalling results in an exit from self-
renewal and pluripotency (Beattie et al., 2005; James et al., 2005; Vallier et al., 2005). 
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SMAD2/3 interact with many transcriptional activators, silencers and nucleosome 
remodelers. During development, transcription factors bind to Smad2/3 and recruit them 
to target loci, whereby SMAD2/3 enable recruitment of transcriptional machinery 
(Dahle et al., 2010; Estaras et al., 2012; Feng et al., 1998; Germain et al., 2000; Kato et 
al., 2002; Pouponnot et al., 1998). It is tempting to speculate that Smad2/3 perform a 
similar role during reprogramming, whereby OCT4, SOX2, KLF4 or C-MYC would 
recruit them to target loci to activate or silence transcription.  Indeed, other groups have 
demonstrated that OCT4 immunoprecipitates with SMAD3, and directs SMAD3 to its 
target loci in mouse ES cells (Mullen et al., 2011). In a situation analogous to 
reprogramming, the over-expression of MyoD1 in mES cells can recruit SMAD3 to 
MYOD1 target sites, away from OCT4 bound sites, while it was not sufficient to 
differentiate ESCs to myoblast in this context. Such data suggests that Smad3 is directed 
to the target sites of whichever master transcription factor is in greatest abundance, 
where Smad2/3 recruit the necessary nucleosome remodelers and transcriptional 
machinery to activate or repress transcription. It is tempting to speculate that during 
reprogramming, Oct4 and perhaps the other Yamanaka factors, are recruiting Smad2/3 
to pluripotency-associated loci to activate transcription.  
 The RNA-seq results demonstrated that some transiently activated gene clusters 
in the control conditions were either not activated at all, minimally activated, or their 
activation was accelerated to earlier time points when reprogramming with addition of 
Smad3CA. Throughout the reprogramming process, the transcript levels for endogenous 
Smad2/3 are certainly lower than the exogenously expressed Yamanaka factors. It was 
not assessed how the levels of active Smad2/3 protein compared to the reprogramming 
factors, but it is possible that over-expressed factors are in far greater abundance than 
endogenous active Smad2/3. Therefore, most of the expressed OCT4, SOX2, KLF4 and 
CMYC could be without SMAD2/3-cofactor, which might compromise their ability to 
activate target genes or result in different transcriptional response at target loci. With 
Smad3CA over expression, and perhaps more potently with Smad2CA/3CA combined, it 
is likely that the Yamanaka factors can more robustly manipulate transcriptional 
programs, enabling a more swift and direct reprogramming process. 
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4.3.4 Bypassing of senescence in the presence of Alki is Smad2/3 independent 
 The resulting increase in reprogramming efficiency with Smad2CA/3CA was not 
as potent as addition of the Alki, suggesting additional mechanisms of Alki action. The 
RNA-seq results confirm that transcript levels from the senescence associated CDKN2a 
(p19ARF/p16Ink4a) and CDKN1a (p21) loci are not strikingly increased or decreased in the 
presence of Smad3CA over expression. Thus, the decreased p19 level in the presence of 
Alki may be a result of other down-stream pathways under TGF-β receptors. TGF-β 
signalling converges on the senescence program through many unique mechanisms. 
While Smad2/3 directly regulate p19ARF thereby activating p53 in fibroblasts, there are 
many reports of Smad2/3 independent TGF-β senescence responses. For example, 
knockdown of p38MAPK severely diminishes the TGF-β induced senescence response 
in MEF (Zheng et al., 2010). Interestingly, p38MAPK directly regulates NF-κB, which 
activates senescence associated secreted proteins (SASPs), as part of a paracrine 
senescence program (Freund et al., 2011). SASPs initiate senescence pathways in 
neighbouring cells, a process that helps establish a robust, localized senescence response 
in tissues and in cells in culture (Acosta et al., 2013; Freund et al., 2011). It is possible 
that SASPs are produced during reprogramming, and may represent part of the TGF-β 
induced p19 senescence response. Intriguingly and unreported in the literature, many of 
the SASP response genes such as IL6, GROα, MCP-2 and IL-1α are massively up 
regulated during reprogramming and down-regulated in iPSCs, as can be observed by 
inspection of time-course RNA-seq data in this thesis and published data sets ((O'Malley 
et al., 2013; Samavarchi-Tehrani et al., 2010). It is therefore likely that the paracrine 
senescence response may represent an, as yet unidentified, barrier to reprogramming and 
that TGF-β ligands may contribute to that response. Future work should explore the 
potential SASP involvement in reprogramming, as targeting of secreted ligands 




5: Chapter 5- How Smad3 enhances reprogramming 
 
5.1 Introduction 
 Extensive work has characterized the role of Smad2/3 transcription factors 
during maintenance of, and transitions between, cellular states. Often the roles of 
Smad2/3 are in providing a rapid, tuneable means to boost or repress transcriptional 
responses. Indeed, short pulses with TGF-β ligands to activate Smad2/3, result in 
hundreds of genes up or down regulated within 1-2 hours (Bertero et al., 2015; Estaras et 
al., 2012; Mullen et al., 2011). How Smad2/3 accomplish such vast and rapid 
transcriptional responses is a result of interaction with a number of transcriptional 
regulators including CBP/p300 co-activators (Feng et al., 1998), NuRD, N-CoR, Sin3 
co-repressor complexes (Akiyoshi et al., 1999; Kim and Lassar, 2003; Luo et al., 1999), 
SWI/SNF chromatin remodelers (Xi et al., 2008), MLL histone H3 Lys4 (H3K4) 
methyltransferase complex (Bertero et al., 2015), and Mediator complex (Kato et al., 
2002). Work in this thesis demonstrated that over expression of Smad2CA/3CA vastly 
accelerates the reprogramming process, and results in over 6-fold increase in efficiency.  
This chapter tests the hypothesis that Smad2CA/3CA boost reprogramming through 
interaction with chromatin remodelers or transcriptional activators, in cooperation with 
the exogenous reprogramming factors, to enable establishment of pluripotency.  
 
5.1.1 Aims of this chapter 
The following experiments aim to investigate the molecular partners and corresponding 
functional consequence of Smad3-protein interactions during reprogramming. Co-
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Immunoprecipitation experiments were preformed to look for Smad3 interactions with 
the reprogramming factors as well as transcriptional regulators. To assess if Smad3 is 
localizing at pluripotency loci, chromatin-immunoprecipitation followed by qPCR 
(ChIP-qPCR) is performed. Finally, to assess the consequence of Smad3 binding to 
genomic regions, histone modifications were also assessed by ChIP-seq.  
 
5.2 Results 
5.2.1 Molecular interactions of Smad3 during reprogramming 
 A primary role for Smad2/3 in cells is to drive transcription of target genes. 
Smad2/3 only weakly bind DNA and require master transcription factors to direct them 
to target loci, providing a mechanism of contextual regulation (Derynck and Zhang, 
2003) (Massague, 2012). To test if the master transcription factors OCT4, SOX2 and 
KLF4 might interact with SMAD3 during reprogramming, co-immunoprecipitation (Co-
IP) followed by western blot analysis was performed. At day 4 of reprogramming, all 
three master transcription factors co-immnoprecipitated with SMAD3, albeit with a very 
weak interaction between SMAD3 and KLF4 (Figure 5.1).    
 SMAD2/3 activate transcription through a number of strategies that include 
recruitment of nucleosome remodelers like SWI/SNF, histone modifying enzymes such 
as the MLL complex, and transcriptional machinery proteins like p300 or mediator (Shi 
and Massague, 2003b). As a broad approach to highlight potential mechanisms of 
Smad3 action, Co-IP was performed to look for Smad3 bound proteins during 
reprogramming. The results reveal that Smad3 interacts with the Dpy30(MLL), p300 





Figure 5.1. Smad3 interacts with reprogramming master transcription factors and 
nucleosome remodelers 
Co-Immunoprecipitation followed by western blot analysis was performed at 
day 4 of reprogramming. Smad3 antibody or IgG was used to pull-down 
bound protein complexes. Precipitated complexes were probed with 
antibodies against the reprogramming master transcription factors as well as 
a panel of nucleosome remodelers and transcriptional activators. Smad3 pull 
down was confirmed by staining the blot with a Smad3 antibody raised in a 
different species. 
 
 As a general model, Smad2/3 provide a link between master transcription factors 
and transcriptional machinery (Massague, 2012; Shi and Massague, 2003b). It is 
possible that with the over-expression of Oct4, Sox2 and Klf4, that endogenous Smad3 is 
a limiting factor for transcription machinery recruitment. If Smad3 is a limiting factor, 
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then over-expression of Smad3CA should boost OCT4 interaction with transcriptional 
machinery. OCT4 immunoprecipitates with DPY30, but not P300, at day 4 of 
reprogramming in control conditions (Figure 5.2a). When over-expressing Smad3CA, 
there was an apparent increase in OCT4-DPY30 interaction (Figure 5.2a). Quantification 
of DPY30 band intensity from 2 independent experiments, demonstrated enrichment of 
OCT4-DPY30 pull-down when over expressing Smad3CA (Figure 5.2b).     
 
 
Figure 5.2. Oct4-Dpy30 interaction enhanced with Smad3CA over-expression 
A) Co-immunoprecipitation followed by western blot analysis at day 4 of 
reprogramming. Antibodies against OCT4 or IgG were used to precipitate 
protein complexes. Complexes were probed with DPY30 or P300 
antibodies. Pull-down was confirmed by staining blot with Oct4 antibody 
raised in a different species. B) Quantification of OCT4 pull-down of 
DPY30 from 3 independent experiments. ImageJ band intensity was 
assessed for DPY30 and OCT4 form IP lysate. The intensity of DPY30 band 
was normalized to Oct4 from the same lysate, to control for differences in 
pull down efficiency and lysate loading. Error bars indicate standard 
deviation (s.d.) from 2 independent experiments.  
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5.2.2 Smad3 chromatin engagement during reprogramming 
 If Smad3 is important for transcriptional activation of pluripotency associated 
genes, then it should bind to pluripotency associated loci regulatory regions during 
reprogramming. Chromatin immunoprecipitation (ChIP) followed by qPCR was 
performed in ES cells and compared to day 8 of reprogramming. Primers were designed 
to assess Smad3 occupancy of pluripotency associated genes, based on previously 
reported binding sites for SMAD3 and OCT4 in ES cells (Chen et al., 2008; Mullen et 
al., 2011). The results confirmed the exisiting literature that SMAD3 binds many 
pluripotency-associated loci including Sall4, Oct4, Fbxo15, Esrrb and Jarid2, Sox2 and 
Nanog in ES cells (Figure 5.3A).  SMAD3 binding at day 8 of reprogramming was then 
examined, revealing that a sub-set of pluripotency loci including Sall4, Oct4, Fbxo15, 
Sox, Nanog2 and Gdf3 were enriched (Figure 5.3B).  Finally, because Smad3 enhanced 
interaction between Oct4 and the histone 3 lysine 4 (H3K4) methytransferase complex 
MLL, H3K4me3 ChIP was performed. H3K4me3 is a histone modification associated 
with actively transcribed genes (Sandstrom et al., 2014). Smad3 is known to interact 
with MLL and deposit H3K4me3 at promoters of genes (Bertero et al., 2015). 
Reprogramming day 8 populations were used for ChIP analysis, revealing H3K4me3 
enrichment at pluripotency loci in the Smad3CA treatment as compared to control 
(Figure5.3C). Interestingly, H3K4me3 marks were enriched even at loci where Smad3 
binding was not detected, which may be a result of indirect affects of Smad3 or the 
limited sensitivity of Smad3 ChIP-qPCR assays. Indeed, a previous ChIPseq study had 
identified Smad3 binding in ES cells, at all the loci tested in our ChIP experiments 




Figure 5.3. Smad3 bind pluripotency loci, and enhances H3K4me3 deposition 
during reprogramming 
A/B) Chromatin immunoprecipitation (ChIP) followed by qPCR was 
performed in (A) ES cells and at (B) day 8 of reprogramming. Smad3 bound 
chromatin was precipitated and then qPCR for various pluripotency loci was 
performed. Day 8 bound genes that were bound in ES cells are shown in 
blue. Fold enrichment refers to enrichment over genomic regions upstream 
of Oct4, where SMAD3/OCT4 do not bind (Chen et al., 2008; Mullen et al., 
2011). C) H3K4me3 ChIP at pluripotency loci transcription start sites, 
comparing enrichment between Smad3CA and control treatments at day 8 of 
reprogramming. Genes with H3K4me3 enrichment, that were bound by 
Smad3 at day 8, are shown in red. Error bars indicate standard deviation 
(s.d.) from 2(a) or 3(b,c) independent experiments with 2 experimental 





5.3.1 Smad3 is a limiting factor for transcriptional activator recruitment 
Previous work has extensively demonstrated a role for SMAD3 in the recruitment of 
transcriptional activators to genomic regulatory regions. One such experiment 
demonstrated that over expression of constitutively active SMAD3 could boost 
recruitment of the methylase JMJD3 to neuronal associated loci both in-vitro and in the 
neural tube of the chick embryo (Estaras et al., 2012). Within 30 minutes of TGF-β 
stimulation in neural stem cells, JMJD3 is recruited to target loci in a Smad3 dependent 
manner (Estaras et al., 2012). Similarly, in human stem cells, Smad3 and Nanog 
coordinate the recruitment of Dpy30, as part of the MLL methyltransferase complex, to 
pluripotency loci to drive transcription (Bertero et al., 2015). A short 2-hour treatment 
with a TGF-β inhibitor, results in reduction of DPY30 and loss of the H3K4me3 mark at 
SMAD3-DPY30 target loci, resulting in reduced transcription (Bertero et al., 2015). In 
the reprogramming context, results presented in this chapter demonstrate that SMAD3 
not only interacts with the reprogramming master transcription factors OCT4, SOX2 and 
to a lesser extent KLF4, but also enhances the interaction between OCT4 and Dpy30, a 
protein that is part of the histone methyltransferase complex MLL. Those findings 
suggest SMAD3 not only provides a link between the master transcription factor and 
transcriptional activators, but also might be a limiting factor in cells, whereby 
transcription factors compete to recruit SMAD3 and associated proteins to their target 
loci. Furthermore, it is worth noting that adding more doxycycline, thereby increasing 
exogenous reprogramming factor expression, does not increase reprogramming 
efficiency, again suggesting the limiting factors are intrinsic to the cells (unpublished 




5.3.2 Smad3 binds pluripotency loci in ES cells and at day 8 of reprogramming 
Results presented in this chapter demonstrate that SMAD3 binds pluripotency-associated 
loci in ES cells and at day 8 of reprogramming. These results suggest SMAD3 is 
involved in direct regulation of pluripotency loci during reprogramming. Indeed, 
Chapter 4 results also demonstrated that pluripotency loci in general, have increased 
levels of transcription by day 10 of reprogramming with Smad3CA. It is tempting to 
speculate that Smad3 might be recruiting nucleosome remodelers or transcriptional 
activators, such as p300, MLL complex (Dpy30) or the SWI/SNF complex (Brg1) to 
bound regions, which results in transcriptional activation. Future work must explore the 
Smad3 dependent recruitment of such factors to pluripotecny loci. 
 At day 8 of reprogramming, SMAD3 binding was not detected at all pluripotency 
loci tested with ChIP-qPCR. The absence of binding could be due to lack of sensitivity 
of the method, or heterogenous reprogramming populations. Given the low efficiency of 
reprogramming, even in our advanced reprogramming system, at day 8 the majority of 
cells will fail to reprogram. Thus, when performing bulk cell analysis, it can be tough to 
distinguish events important for reprogramming, and those that are not important to the 
process. However, many of the loci bound by Smad3 at day 8 of reprogramming had 
enriched H3K4me3 and increased transcriptional activity by day 10 in the RNA-seq 
data. These data at least suggest a correlation between Smad3 binding and genes which 
are eventually activated. Alternatively, RNA-seq profiling demonstrated many changes 
in global transcriptional patterns between Smad3CA and control experiments, revealing 
that Smad3CA reprogramming bypasses certain aberrant reprogramming transcriptional 
states. Such results might explain how reprogramming is accelerated by Smad3CA 







6: Supplementary Chapter 6- Smad3CA potentiates 
other master transcription factor mediated cell identity 
conversions  
6.1.1 Note  
Work in this thesis lead to the hypothesis that Smad2/3 could be involved in many 
unique cell identity changes. Collaborating labs performed all of the experiments in this 
chapter. The results are presented below to demonstrate the impact of the findings from 
this thesis. All B-cell to macrophage and myoblast to adipocyte conversion experiments 
were performed by Bruno DiStefano and Tian Tian from Thomas Graf’s lab in 
Barcelona, Spain. Ulrich Pfisterer and Daniella Rylander performed the induced neuron 
work, from Malin Parmar’s lab in Lund University, Sweden.  
 
6.2 Introduction 
 While induced pluripotent stem cells (iPSCs) have the ability to generate any cell 
or tissue type, transdifferentiations from one somatic cell type to another are also 
possible and hold great potential for regenerative medicine. Similarly to iPSCs, 
transdifferentiation is a cell identity conversion accomplished by over expression of 
master transcription factors of the desired cell types. The list of possible cell identity 
conversions is expanding rapidly, ranging from fibroblast to neuron, B-cell to 
macrophage, myoblast to brown fat, and fibroblast to cardiomyocyte among many others 
(Graf, 2011). The underlying mechanisms of various transdifferentiation processes have 
begun to emerge, which ultimately involve the gradual reorganization of chromatin, 
driven by nucleosome remodelling and histone modifications, establishing a new 
transcriptional network to generate the final cell type (Di Stefano et al., 2014; Lee et al., 
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2014; Tonge et al., 2014; Vierbuchen and Wernig, 2012; Wapinski et al., 2013). 
Transdifferentiation processes range in duration from a few days, in the case of B-cell to 
macrophage, to many months for the conversion of fibroblast to mature neuron 
(Bussmann et al., 2009; Feng et al., 2008; Pereira et al., 2014; Pfisterer et al., 2011). 
There is almost no information as to why such variances occur; why some cell types are 
easier to generate than others, and what are the major roadblocks. Furthermore, the 
question remains if there are shared roadblocks or cellular machinery amongst all forced 
cell identity change processes.  
 Recent work illuminated the contextual nature of TGF-β signalling, 
demonstrating that Smad3 is directed to target loci by cell type specific master 
transcription factors (Mullen et al., 2011). Chromatin immunoprecipitation (ChIP) 
experiments revealed that SMAD3 binds entirely unique regions across the genome in a 
given cell type, co-localizing with OCT4, SOX2 and NANOG in ES cells, PU.1 in pro-B 
cells, and MYOD1 in Myotubes. Importantly, expression of MyoD1 in ES cells directed 
SMAD3 to bind MYOD1 binding sites, whilst SMAD3 remained bound to OCT4 bound 
regions. Those results reveal how transcription factors might compete to commandeer 
Smad3 to their target loci to activate transcription and force cell identity changes. The 
master transcription factors that drive these cell identity conversions rely upon cofactors 
to recruit nucleosome remodelers and transcriptional machinery to target loci. Here we 
hypothesized that different forced cell identity conversion systems, with unique sets of 
master transcription factors, might rely upon Smad2/3 to facilitate the conversion 
process. 
 Here we studied the forced cell identity conversion of B cells to macrophages, 
myoblasts to adipocytes, and fibroblasts the neurons with unique sets of master 
transcription factors and addition of Smad2CA/3CA. B cells can be converted to the 
developmentally related macrophage by expression of a single transcription factor, 
C/EBPα or C/EBPβ (Xie et al., 2004). Within just 5 days of C/EBPα expression in B cell 
progenitors, up to 80% of cells have completely down-regulated the B-cell 
transcriptional program including the surface antigen CD19, and up-regulated the 
macrophage specific transcription network including the Mac-1 surface receptor. 
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Myoblasts can also be converted to adipocytes (brown fat) upon over expression of 
C/EBPβ and PRDM16. Brown fat cells and myoblasts arise from a common progenitor, 
whereby fate determination is regulated by the transcription factor PRDM16 (Kajimura 
et al., 2009). Loss of PRDM16 in-vitro in precursor cells result in loss of brown fat 
populations, favouring myogenic lineages, and ectopic expression of PRDM16 in 
C2C12 myoblasts drives conversion to a brown fat cell fate (Seale et al., 2009). It was 
subsequently demonstrated that PRDM16 requires endogenous C/EBPβ to initiate the 
conversion, and over expression of C/EBPβ could not only enhance the process but 
enable conversion of fibroblasts to brown fat (Kajimura et al., 2009). Finally, in 2010, it 
was discovered that human fibroblasts could be converted to neurons by over-expression 
of just 3 neuronal transcription factors: Ascl1, Brn2 and Myt1l (Vierbuchen et al., 2010).  
The resultant induced neurons (iNs) exhibit typical neuronal morphology with axonal 
outgrowths, express neuronal genes, fire action potentials and generate functional 
synapses (Vierbuchen et al., 2010).  It was subsequently identified that addition of 
NeuroD1 could boost the conversion process and maturity of resultant neurons (Pang et 
al., 2011). Because Smad2/3 interact with many cell-type specific master transcription 
factors, we tested if Smad2/3 could boost diverse cell identity conversion systems in 
combination with other cell type specific master transcription factors.  
6.2.1 Aims of this chapter 
This chapter tests the hypothesis that Smad2/3 are shared underlying cellular machinery 
involved in diverse cell identity conversions with master transcription factors. The 
contribution of Smad3 to the processes of converting B-cells to macrophages, myoblasts 
to adipocytes, and fibroblasts to neurons are investigated. The conversion processes are 
accomplished by over expression of cell type specific master transcription factors, in 
various starting cells including from mouse and human origin, with addition of 
Smad2CA or Smad3CA. Functional readout varies depending on converted cell types, 
but involves microscopy, FACS analysis, and electrophysiology with patch-clamp 
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analysis. The results present an assessment of conversion efficiency and maturity of the 
converted cell types. 
6.3 Results 
6.3.1 Smad2CA/3CA boost the conversion of B-cell to Macrophage with C/EBPα 
 To test if Smad2/3 could boost the conversion of B cells to macrophages, B cell 
progenitors were harvested from C57Bl/6J mice using magnetic beads selection to 
capture CD19 positive cells, as previously described (Xie et al., 2004). Retroviral 
vectors were used to express C/ebpα in combination with Smad3CA or Smad2CA, and 
transdifferentiation progression was monitored with CD19 and MAC-1 expression by 
FACS analysis. Within 6 days of C/ebpα expression alone, 99% of starting pre-B cells 
down regulated CD19 expression and gained the macrophage marker Mac-1 expression 
(Figure 6.1). With the addition of Smad3CA or Smad2CA expression, the up regulation 
of Mac-1 expression was significantly accelerated, with ~2-fold increase in MAC-1 
expression at day 3. Interestingly, the down regulation of CD19 was unaffected by 





Figure 6.1. Conversion of B cell to macrophage with C/EBPα is enhanced with 
Smad2CA/3CA.  
A) B cells were converted to macrophages by retroviral-transduction of 
C/EBPα with addition of Smad2CA or Smad3CA. B/C) FACS analysis 
monitoring the B cell surface marker CD19 and macrophage marker MAC-1 
expression during the 6-day transdifferentiation process. Graph values 
represent average of 2 independent experiments. **P-value <0.01 based on a 
two-sided t-test. 
6.3.2 Myoblast to adipocyte transdifferentiation with PRDM16 and C/EBPβ is 
enhanced by SMAD2CA/3CA 
 To examine if Smad2/3 can boost myoblast to adipocyte cell conversion, Prdm16 
and C/ebpβ were transduced together with Smad2CA or Smad3CA into C2C12 
myoblasts (Figure 6.2A). After 6 days of induction, wells were stained with Oil Red O, 
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which stains the lipids and triglycerides within fat cells. In the presence of Smad2CA or 
Smad3CA, adipogenesis conversion was boosted, showing a ~20% increase in entire 




Figure 6.2. Smad2CA/3CA boost myoblast to adipocyte transdifferentiation. 
A) C2C12 myoblasts are converted to adipocytes with expression of C/ebpβ 
and Prdm16, with addition of Smad2CA or Smad3CA. B) Oil Red O staining 
of cells 6 days post induction of transgenes. C) Quantification of Oil Red O 
images. D) Examples of entire wells stained with Oil Red O. Graphs 
represent 3 averages of 2 independent experiments with 3 replicates. **P-
value <0.01 based on a two-sided t-test. 
6.3.3 Induced neuron maturity is increased when generated with addition of 
Smad2CA/3CA 
 The HFL1 Human fibroblast line was transduced with lentiviral expression 
vectors encoding Ascl1, Brn2, Myt1l and NeuroD1 (ABMN) with addition of Smad2CA 
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or Smad3CA (Figure 6.3A). Neuronal purity of transdifferentiated cultures was assessed 
using NCAM staining at day 25, revealing no difference between control (ABMN) and 
addition of Smad2CA or Smad3CA  (Figure 6.3B). To assess neuron functional 
maturity, whole cell patch clamp analysis was performed at day 25, a time at which 
NCAM positive cells hare maximal and no new neurons are generated. 
Electrophysiology recordings revealed that control neurons, generated with only ABMN, 
did not have the ability to fire action potentials (Figure 6.3C and D.) at this early time 
point, consistent with previous reports {Pfisterer, 2011 #837}.  With addition of 
Smad3CA or Smad2CA to ABMN conversions, a remarkable increase in neuronal 
maturity was observed, with 66% and 78% of neurons able to fire action potentials, of 
which 27% and 33% were able to fire repetitive action potentials respectively (Figure 
6.3 C and D). Moreover, strikingly, 36% of neurons generated with addition of 
Smad3CA demonstrated spontaneous action potential activity at day 25, a feature of 
highly mature neurons able to send and receive synaptic inputs, which are typically only 
observed after 90 days of conversion (Figure 6.3D) (Pereira et al., 2014). 
 
 
Figure 6.3. Smad2CA/3CA enhances induced neuron maturity 
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A) Human HFL1 fibroblasts are converted to induced neurons by lentiviral 
transduction of Ascl1, Brn2, Myt1L and NeuroD1, with addition of 
Smad2CA/3CA. B) FACS analysis quantifying percent of NCAM+ cells 
(neuronal purity) at day 25 of the conversion process. C) Representative 
whole cell patch clamp traces of membrane sodium and potassium 
currents following induced action potentials. Far right demonstrates 
spontaneous synaptic activity D) Electrophysiology characteristics of 
cells recorded at day 25 of induction. Error bars represent standard 
deviation form 2 independent experiments with 2 technical replicates. 
6.4 Discussion 
6.4.1 Smad2/3 potentiate diverse transdifferentiation processes   
 It was possible that Smad2/3’s role in induced pluripotency was limited to 
reprogramming and cell identity conversions from fibroblasts. This chapter explored the 
ability of Smad2/3 to boost transdifferentiation processes, including from cells 
developmentally distinct from fibroblasts. The results demonstrate that Smad2/3 can act 
in many diverse cell types, and boost the conversion of distinct transdifferentiation 
processes in combination with various master transcription factors (Figure 6.4). It is 
possible that Smad3 (or Smad2) may interact with the master transcription factors of 
macrophages, brown fat cells or neurons, in a similar fashion as during induced 
pluripotency, where Smad3 interacts with Oct4 and boosts its interaction with the MLL 
histone modifying complex (Figure 5.2 and 6.1). Interestingly, interaction between the 
pre-B cell transcription factor PU.1 and Smad3 has been previously demonstrated 
(Mullen et al., 2011). Smad3 and PU.1 bind overlapping genomic loci in pre-B cells and 
PU.1 knockdown results in reduction of Smad3 occupancy at sites bound by PU.1. 
Those results suggested that Smad3 was recruited by PU.1 to target loci, analogously to 
Smad3 recruitment to pluripotency sites by Oct4. Given PU.1 is necessary for 
transdifferentiation of pre-B cells to macrophages, and Smad3 can boost the process, it 




Figure 6.4. SMAD2/3 potentiate cell identity conversions with master transcription 
factors 
Cell identity conversions induced by over expression of master transcription 
factors (TFs) involve epigenetic and transcriptional changes throughout the 
conversion process. Smad2/3 interact with many different cell-type specific 
master TFs, as well as coactivators/corepressors, such as p300, MLL 
complex and the SWI/SNF complex. During cell identity conversion, 
Smad2/3 provide a bridge, linking master TFs with various cofactors, which 
potentiate the epigenetic and transcriptional changes. 
 
6.4.2 Smad2/3 promote neuronal maturity  
While the discovery of B cell to macrophage and myoblast to brown fat 
transdifferentiation were remarkable feats of cellular engineering, it still remained an 
open question as to the limitations of cell fate conversions. For example, the question 
remained if cells could be transdifferentiated to cells of a different developmental germ 
 
 115 
layer. Upon the discovery of iPSCs, demonstrating a remarkable reversion of fibroblast 
cell fate, it seemed any cell fate conversions was possible given the right set of 
transcription factors. Perhaps the earliest and most concrete demonstration of 
transdifferentiation between different developmental germ layers was achieved when 
fibroblasts were converted to neurons (Vierbuchen et al., 2010). The finding that 
Smad3CA can boost the conversion by enhancing neuronal maturity, accelerating the 
process by months, was a very exciting finding. It was a powerful discovery, 
demonstrating Smad3 can boost conversions involving different developmental germ 
layers, further supporting a more ubiquitous role for Smad2/3 is many cell fate changes. 
 Whole cell patch clamp analysis is a technique commonly used to assess a 
hallmark of neuronal activity: the ability to control ionic passage and transmit electrical 
signals across the membrane (Karmazinova and Lacinova, 2010). One can measure both 
single and repetitive action potentials from individual neurons using the whole cell patch 
clamp approach. Whilst Smad2/3 did not enhance the efficiency of converting 
fibroblasts to neurons, the induced neurons demonstrated striking maturity when 
converted with the addition of Smad2CA or Smad3CA. Whole cell patch clamp analysis 
revealed that, only with the addition of Smad2CA or Smad3CA, induced neurons fired 
action potentials at day 25 of conversion. Furthermore, roughly one third of neurons 
produced with addition of Smad2CA/3CA fired repetitive action potentials, a trait 
indicative of advanced maturity (Pereira et al., 2014).  Recent work has highlighted 
important roles for Smad2/3 during neuronal differentiation, suggesting that Smad2/3 
are major determinants of the neural developmental program (Estaras et al., 2012; 
Garcia-Campmany and Marti, 2007; He et al., 2014; Jia et al., 2009). Perhaps the best 
example of Smad3 activity was demonstrated by over expression of Smad3CA in the 
chick spinal cord, which resulted in rapid down regulation of neural precursor genes 
such as Id’s and Sox2, and activation of neural commitment genes such as NeuroM, 
HuCD and Tuj1 (Estaras et al., 2012; Garcia-Campmany and Marti, 2007). SMAD3 
recruits the H3K27me3 histone demethylase JMJD3 to neural promoters, which 
produces a transcriptional permissive state (Estaras et al., 2012). Similar roles for Jmjd3 
have also been demonstrated in neural stem cells of the subventricular zone, whereby 
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Jmjd3 is required for neurogensis in adult mice (Park et al., 2014). Previous findings are 
therefore in agreement with work from this thesis, demonstrating a crucial role for 
Smad3 in directing neuronal maturation. It is tempting to speculate that Smad3, in 
conjunction with histone remodelers such as Jmjd3, may orchestrate chromatin 





7: General Discussion 
 
7.1 General contributions of this thesis  
 The ability to reprogram somatic cells to a pluripotent state holds tremendous 
promise for regenerative medicine. One of the more directly applicable findings from 
this work is the increased efficiency and acceleration of the generation of iPSCs with 
Smad2CA/3CA. Improving the efficiency and accelerating reprogramming will allow 
ease of generation of iPSCs and will make the technology more attractive for potential 
clinical uses, as well as large scale disease modelling approaches, where time and 
financial burden are of major consideration. Improving the efficiency of fibroblast 
reprogramming may also benefit the reprogramming of other cells types that may have 
more direct clinical relevance, such as the reprogramming of peripheral blood, which is 
an attractive alternative to fibroblasts due to the ease of cell extraction (Staerk et al., 
2010).  Excitingly, work from this thesis has lead to a collaborative project with the 
company Roslin Cells, based in Edinburgh, to test Smad2CA/3CA’s ability to boost 
reprogramming of peripheral blood in hopes of making the technology more robust for 
clinical applications.  
 One caveat of this work is that the quality or stability of iPSC generated in the 
presence of Smad2CA/3CA was not assessed. The use of the Nanog-GFP reporter is a 
valuable tool to suggest the acquisition of a pluripotent like state, but does not suffice to 
prove the resultant cells are bona fide iPSCs. While the global transcription profiles of 
resultant iPSCs in the presence of Smad3CA are very similar to ESCs, a more 
comprehensive battery of pluripotency tests is required. For example, the ability of the 
cells to give rise to teratomas upon subcutaneous injection into mice, contribute to 
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chimeras, integrate into blastocysts, and be transmitted through the germline should be 
assessed. We are currently performing such characterizations. 
 Years of work exploring TGF-β signalling in embryogenesis have highlighted 
roles for Smad2/3 in differentiation and specification of the mesendoderm germ lineage. 
Such seminal works were the foundation for the hypothesis that TGF-β inhibitor with 
Alki worked to alleviate mesenchymal signalling during the reprogramming of 
fibroblasts (Ichida et al., 2009a; Li et al., 2010a; Polo and Hochedlinger, 2010). 
However, while it is clear that TGF-β and Smad2/3 are necessary for primitive streak 
formation and driving the mesenchymal transcriptional program, conditional 
knockout/rescues and chimeric embryos have highlighted that TGF-β-Smad2/3 
knockouts exhibit phenotypes across all three embryonic germ layers throughout 
development. Striking examples of conditional or partial Smad2/3 knockout phenotypes 
include the malformation of embryonic anterior neural patterning, endoderm defects 
giving rise to liver failure, and onset of colorectal cancers with near 100% penetrance 
(Vincent et al., 2003; Weinstein et al., 2001; Yang et al., 1999; Zhu et al., 1998). To 
date, there is tenuous evidence of TGF-β inhibition contributing to down-regulation of 
mesenchymal signalling during reprogramming. Experiments in this thesis further 
demonstrate that transition to the epithelial program with E-cadherin expression, is not 
enhanced by TGF-β inhibition. Finally, over expression of Smad2CA/3CA during 
reprogramming did not increase the mesenchymal gene program, but rather boosted 
acquisition of pluripotency. It is clear that TGF-β-Smad2/3 signalling is not 
mesenchyme specific and this thesis further clarifies a model whereby TGF-β-Smad2/3 
signalling is a product of the current state of the cell, acting more to potentiate, rather 
than direct, a given transcriptional program. 
 Recent work describes essential roles for the TGF-β receptor Alk5, as well as 
Smad3, in accelerating neuronal differentiation from neural stem cells in both neural 
tube development and adult stem cell populations (Estaras et al., 2012; Garcia-
Campmany and Marti, 2007; He et al., 2014; Jia et al., 2009). Work performed in this 
thesis describes the accelerated maturation of induced neurons with the addition of 
Smad2CA/3CA. Production of mature neurons, with the ability to fire action potentials 
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and integrate into neuronal networks, has long been a challenge in the neuron 
differentiation field (Chambers et al., 2009; Kriks et al., 2011; Miller et al., 2013; 
Osakada et al., 2009; Saha and Jaenisch, 2009). The strikingly advanced maturity of 
induced neurons produced with addition of Smad2CA/3CA has initiated a new project, 
investigating neuronal maturation in vitro and in vivo, in collaboration with Malin 
Parmar’s group in Lund. The birth of such projects illuminates how the study of basic 
underlying mechanisms of induced pluripotency can transition to translational 
applications. 
 This work has demonstrated that Smad2/3 are not only shared underlying cellular 
machinery for reprogramming, but also a powerful tool that can potentiate master 
transcription factor mediated cell identity conversions. Such findings provide the 
groundwork for exploring cellular identity changes on the basis of what the shared 
roadblocks are and how we can manipulate cells to be more permissive to any cell 
identity conversion. The overarching process of rearranging chromatin and 
transcriptional networks to change cell identity, is a shared feature of all cell identity 
changes to some degree (Ho and Crabtree, 2010; Sisakhtnezhad and Matin, 2012). 
Furthermore, certain chromatin states with specific histone modifications, are associated 
with transcription factor accessibility and tightly correlate with transcriptional activation 
or repression (Papp and Plath, 2013; Soufi et al., 2015; Wapinski et al., 2013). It was 
therefore not entirely surprising to find chromatin remodelling cofactors like Smad2/3 to 
be involved in multiple cell identity conversions. The finding that Smad2/3 might be 
limiting factors for transcriptional activation further suggests a model whereby 
transcription factor activity is limited by availability of chromatin remodelling factors 
and transcriptional machinery. It will be interesting to identify what other major 
‘bottleneck factors’ exist, and if they can be manipulated like Smad2/3 to boost the 
production of more challenging cell types. It is likely that future work exploring 
commonalities amongst forced cell identity changes will begin with examination of 
chromatin remodelling factors.   
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7.2 Future Directions 
7.2.1 Characterizing TGF-β initiated senescence during reprogramming 
Work in this thesis revealed a bypassing of p19-induced senescence during 
reprogramming in the presence of the TGF-β inhibitor Alki.  As discussed in chapter 4, 
TGF-β directly activates p38MAPK, which is linked to activation of p19ARF through 
mechanisms that likely involve regulation of senescence associated secreted proteins 
(SASPs) (Zheng et al., 2010). P38MAPK is involved in regulation of NF-κB, which 
regulates SASPs as part of the paracrine senescence program (Freund et al., 2011). 
Indeed, reports have demonstrated TGF-β ligands induce SASP responses in 
neighbouring cells (Hoare and Narita, 2013; Hubackova et al., 2012). Probing 3 
independent reprogramming data sets revealed that SASPs are robustly up regulated 
during reprogramming, representing a possible undiscovered reprogramming roadblock. 
Future work should involve investigating the SASP response during reprogramming and 
possible link to TGF-β signalling.    
7.2.2 Deepening our understanding of Smad2/3 activation of pluripotency 
associated genes  
Future work must clearly demonstrate that SMAD2/3 are recruiting nucleosome 
remodelers, histone modifiers or other transcriptional machinery to target loci in the 
reprogramming context. It is possible the accelerated activation of pluripotency genes in 
the presence of Smad2CA/3CA during reprogramming could be a secondary effect. 
While this thesis revealed Smad3 binds pluripotency-associated loci during 
reprogramming, to clearly demonstrate an effect, it is necessary to show Smad2/3 
dependent recruitment of nucleosome remodelers or transcriptional regulators to those 
sites. One such experiment could involve a short burst of Smad3CA expression, followed 
by ChIP analysis. Preliminary work has demonstrated that activation of dox inducible 
Smad3CA at day 6 of reprogramming, gave rise to substantially more Nanog-GFP+ 
colonies just 48-hours later. Thus, it is clear that Smad3CA can have effects on 
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pluripotency loci such as Nanog over short duration of expression, providing a means to 
test the direct effects of the protein during reprogramming. ChIP analysis can then assess 
if nucleosome remodelers or transcriptional activator candidates bind pluripotency loci 
more robustly with short pulses of Smad3CA expression. Candidates should include all 
of which co-immunoprecipitated with SMAD3 at day 4 of reprogramming, such as 
P300, MLL (DPY30) and SWI/SNF (BRG1) complexes. Following those experiments, it 
might be interesting to examine histone modifications that result from such recruitment, 
and there association with transcriptional activation.  
 As a complementary approach, an assay for transposon accessible chromatin 
using sequencing (ATAC-seq) has been undertaken to assess chromatin dynamics during 
reprogramming with or without Smad3CA over-expression. The recently described 
technique utilizes the TN5 tranposase to insert sequencing adaptors throughout the 
genome, whereby nucleosome free DNA regions tend to have more adaptor insertions 
(Buenrostro et al., 2013). Upon sequencing, one can visualize the occupancy of 
nucleosomes across the genome by deductive analysis, whereby nucleosome rich regions 
will have fewer sequencing reads. The approach enables the assessment of global 
chromatin status at an extraordinary resolution (~10bp). I have performed ATAC-seq 
over a 15 day reprogramming experiment, every 2 days, which will enable the 
assessment of global chromatin changes elicited by Smad3CA. These results should 
reveal the nature of Smad3 chromatin reorganization, and further our understanding of 
Smad3 contribution to cell identity changes. Furthermore, this will be the first 
experiment to probe global chromatin architecture in such fine detail throughout a 
reprogramming experiment, which will be of tremendous benefit to understand how 
gross chromatin architecture in various genomic regions influence the outcome of 
reprogramming, and how it might be reorganized throughout the process. 
7.2.3 Investigations of neurogenesis in the presence of Smad2CA/3CA 
One of the more striking findings from this thesis was the advanced induced neuronal 
maturity when generated in the presence of Smad2CA/3CA. It will be interesting to look 
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in further detail as to the mechanism of Smad2CA/3CA actions during neurogenesis. In 
a similar method to our reprogramming studies, we are preparing time course RNA-seq 
and ATAC-seq samples to assess global transcriptional and chromatin states throughout 
the induced neuron transdifferentiation process. The idea will be to assess which 
pathways are most differentially activated with Smad3CA, to hopefully identify key 
players involved in maturation of induced neurons. The ATAC-seq analysis should 
further reveal global chromatin states, revealing how chromatin architecture may 
correlate to neuronal maturity. The work will also investigate how the resulting neurons 
perform upon transplantation and their ability to integrate within host neuronal 
networks, a current challenge in the field. Furthermore, little is known about the 
underlying mechanisms of the transition from fibroblast to neuron, and how they relate 
to normal neuron development form ES cells in-vivo or in-vitro. Recent studies have 
described roles for Smad3 and TGF-β receptors for neuronal differentiation both in vitro 
and in the developing neural tube. There are strong links between the TGF-β pathway 
and chromatin remodellers important for neural differentiation. It will be interesting to 
assess if similar mechanisms are at play for induced neurons, asking if the 
transdifferentation process shares any similarities to normal developmental contexts.  
7.3 Closing remarks 
 Since the discovery of iPSCs in 2006, an enormous body of work has been 
dedicated to understand how such an inefficient process occurs. With each discovery, we 
learn more about the underlying cellular machinery required to orchestrate 
reprogramming, identify the major barriers, and continuously improve the efficiency of 
the process. Such advances have undoubtedly enabled a widespread use of the 
technology, as indicated by the shear number of publications that have utilized iPSCs. 
Ranging from disease modelling and drug discovery to tissue engineering, the benefits 
of iPSCs have already been realized. It is an exciting prospect to consider the unlimited 
potential of such a technology, and we now await the first clinical trials using iPSCs as a 
source of cells for regenerative therapies.  
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 The fact that iPSCs are widely used and making their way to the clinic, does not 
mean we no longer need to study the reprogramming process. Recent publications are 
still reporting reprogramming efficiencies of 1-5%, with exceptional cases claiming 
higher efficiency, revealing there are still major unidentified roadblocks. While it may 
not be necessary to increase reprogramming efficiency, the inefficiency of the system 
itself reveals that there are many characteristics of cell identity conversions we still do 
not understand. Through studies of reprogramming, we can better manipulate cell 
identity conversions, as exemplified in this thesis. The generation of various cells and 
tissues types, hold tremendous promise not only for regenerative therapies, but also to 
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